CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10719292,107192923,3,F,,20201014,20150119,20201026,EXP,,CA-ROCHE-1522743,ROCHE,,54,YR,,M,Y,,,20201026,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,107192923,OT,,,,,,,,,107192923,1,Bipolar disorder
11003783,110037833,3,F,2008,20201112,20150409,20201118,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-022290,BRISTOL MYERS SQUIBB,"FERNANDO I, SCOTT G. A CASE OF MULTICENTRIC CASTLEMAN^S DISEASE IN HIV INFECTION WITH THE RARE COMPLICATION OF ACQUIRED ANGIOEDEMA. INTERNATIONAL JOURNAL OF STD AND AIDS. 2014;25 (7):523-5",37,YR,,F,Y,,,20201118,,MD,GB,GB,EFAVIRENZ.,Angioedema;Castleman's disease;Immune reconstitution inflammatory syndrome,110037833,HO,,,110037833,1,200403,,,,110037833,1,HIV infection
11042847,110428473,3,F,200408,20200928,20150417,20201007,EXP,,GB-AUROBINDO-AUR-APL-2015-03298,AUROBINDO,EFAVIRENZ/LAMIVUDINE/TENOFOVIR-MULTICENTRIC CASTLEMAN^S DISEASE AND ACQUIRED ANGIOEDEMA IN THE CONTEXT OFIRIS: CASE REPORT. 2015,37,YR,,F,Y,,,20201007,,,COUNTRY NOT SPECIFIED,GB,EFAVIRENZ.,Anaemia;Angioedema;CD4 lymphocytes increased;Castleman's disease;Condition aggravated;Haemoglobin decreased;Haemolysis;Peripheral swelling;Pruritus;Swelling face;Viral load decreased,110428473,HO,,,110428473,1,200403,,,,110428473,1,Genital herpes
11858664,118586644,4,F,20010322,20201123,20151222,20201203,EXP,,US-009507513-01050823,MERCK,,1,DY,,M,Y,3.24,KG,20201203,,CN,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,118586644,CA,,,118586644,1,20001109,20000810,,,118586644,1,HIV infection
12764792,127647923,3,F,,20201008,20160921,20201022,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076797,BRISTOL MYERS SQUIBB,"GRIMES R, GILLEECE Y, APPLEBY T, STOCKWELL S, PINTO-SANDER N, SAHABANDU T, ET AL. A CASE OF HEREDITARY COPROPORPHYRIA PRECIPITATED BY EFAVIRENZ. AIDS. 2016;30(13):2142-3",25,YR,,M,Y,,,20201022,,MD,GB,GB,EFAVIRENZ.,Acquired porphyria,127647923,OT,,,,,,,,,127647923,1,HIV infection
13906408,139064086,6,F,,20201029,20170825,20201101,EXP,,CA-009507513-0809CAN00001,MERCK,,54,YR,,M,Y,,,20201101,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,139064086,DE,,,139064086,1,20070620,,,,139064086,1,HIV infection
14662859,146628593,3,F,,20180306,20180321,20201229,EXP,,TH-NOVITIUM PHARMA LLC-2018-TH-000005,NOVITIUM PHARMA,"TEMPARK T, SATAPORNPONG P, RERKNIMITR P, NAKKAM N, SAKSIT N, WATTANAKRAI P, ET AL..DAPSONE-INDUCED SEVERE CUTANEOUS ADVERSE DRUG REACTIONS ARE STRONGLY LINKED WITH HLA-B*13:01 ALLELE IN THE THAI POPULATION.PHARMACOGENETICS AND GENOMICS.2017;27(12):429-437.",57,YR,A,F,Y,,,20180321,,HP,TH,TH,EFAVIRENZ.,Drug reaction with eosinophilia and systemic symptoms;Hepatitis;Leukocytosis;Product use in unapproved indication;Purpura;Pyrexia;Rash maculo-papular;Skin exfoliation,146628593,LT,,,,,,,,,146628593,1,Prophylaxis against HIV infection
14916965,149169653,3,F,201801,20201030,20180520,20201112,EXP,,PHHY2018ZA002551,NOVARTIS,,,,,F,Y,,,20201112,,MD,ZA,ZA,EFAVIRENZ.,Maternal exposure during pregnancy;Retroviral rebound syndrome,149169653,OT,,,149169653,3,,20171204,,,149169653,1,Tuberculosis
14991292,149912923,3,F,20180601,20201030,20180608,20201103,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2018GSK101917,VIIV,,,,,F,Y,66.5,KG,20201103,,MD,ZA,ZA,EFAVIRENZ.,Transaminases increased,149912923,OT,,,149912923,1,20180314,20180605,,,149912923,1,HIV infection
15115814,151158146,6,F,20171006,20201007,20180706,20201013,EXP,,GB-MYLANLABS-2018M1048354,MYLAN,,16,WK,,M,Y,,,20201013,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,151158146,DE,,,151158146,1,20171006,20180205,,,151158146,1,HIV infection
15193162,151931623,3,F,,20201002,20180725,20201009,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-068468,BRISTOL MYERS SQUIBB,"APONTE J, SALONIA J, STOEVER J, SHUJAAT A. WHEN NOT TO CHOOSE APIXABAN: A CASE OF APIXABAN FAILURE. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2018;197",64,YR,,M,Y,,,20201009,,HP,US,US,EFAVIRENZ.,Acute myocardial infarction;Drug interaction;Pulmonary embolism,151931623,OT,,,,,,,,,151931623,1,Cerebrovascular accident prophylaxis
15463860,154638606,6,F,2018,20201216,20181004,20201223,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2018GSK177825,VIIV,,6,WK,,,Y,,,20201223,,MD,ZA,ZA,EFAVIRENZ.,Umbilical hernia,154638606,CA,,,154638606,1,20180628,20200326,,,154638606,1,HIV infection
15617535,156175355,5,F,,20201228,20181114,20201230,EXP,,PHHY2018PT154439,NOVARTIS,,49,YR,,M,Y,,,20201230,,HP,PT,PT,EFAVIRENZ.,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,156175355,OT,,,,,,,,,156175355,1,Disseminated tuberculosis
15661445,156614454,4,F,2018,20201118,20181127,20201126,EXP,,US-GILEAD-2018-0376064,GILEAD,,38,YR,A,M,Y,,,20201126,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Pain,156614454,OT,,,156614454,1,20111221,20120120,,,156614454,1,HIV infection
15773855,157738552,2,F,,20200928,20181229,20201006,EXP,,DE-AUROBINDO-AUR-APL-2018-063436,AUROBINDO,,52,YR,,F,Y,,,20201006,,HP,DE,DE,EFAVIRENZ.,"Abnormal behaviour;Acute psychosis;Cognitive disorder;Delusion;Depressed mood;Disturbance in attention;Hallucinations, mixed;Impulse-control disorder;Irritability;Memory impairment;Personality change;Psychomotor hyperactivity;Tension",157738552,HO,,,,,,,,,157738552,1,HIV infection
15894554,158945542,2,F,200311,20200917,20190131,20201001,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2005-FF-00956FF",BOEHRINGER INGELHEIM,,36,YR,A,F,Y,82,KG,20201001,,CN,FR,FR,EFAVIRENZ.,Abdominal pain;Chills;Diarrhoea;Eyelid oedema;Lip oedema;Pyrexia;Rash;Thrombocytopenia,158945542,HO,,,158945542,1,20051201,20051202,,,158945542,1,Chills
15901024,159010242,2,F,,20201027,20190201,20201104,EXP,,US-GILEAD-2019-0387831,GILEAD,,,,A,F,Y,121.11,KG,20201103,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Osteoporosis;Pain;Renal impairment,159010242,OT,,,159010242,1,2005,20141113,,,159010242,1,HIV infection
15934516,159345166,6,F,20050813,20201007,20190207,20201013,EXP,,FR-MYLANLABS-2019M1011150,MYLAN,,25,YR,,F,Y,56,KG,20201013,,CN,US,FR,EFAVIRENZ.;SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,159345166,HO,,,159345166,1,20050523,20050908,,,159345166,1,HIV infection
15989803,159898033,3,F,,20201123,20190221,20201201,EXP,,BW-MYLANLABS-2019M1015918,MYLAN,,,,N,,Y,,,20201201,,HP,BW,BW,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,159898033,CA,,,,,,,,,159898033,1,Product used for unknown indication
15998853,159988533,3,F,,20201125,20190223,20201201,EXP,,CA-009507513-1902CAN006364,MERCK,,52,YR,,M,Y,,,20201201,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,159988533,OT,,,,,,,,,159988533,1,HIV infection
16022383,160223834,4,F,,20201123,20190301,20201126,EXP,,BW-AUROBINDO-AUR-APL-2019-009434,AUROBINDO,,,,,,Y,,,20201126,,MD,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Stillbirth,160223834,OT,,,,,,,,,160223834,1,Product used for unknown indication
16213545,162135456,6,F,2009,20201103,20190418,20201112,EXP,,US-GILEAD-2019-0402572,GILEAD,,59,YR,A,F,Y,81.63,KG,20201112,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Exostosis;Osteoarthritis;Pain;Renal failure;Renal impairment;Spinal compression fracture,162135456,OT,,,162135456,1,20090207,20160812,,,162135456,1,HIV infection
16229747,162297476,6,F,20071207,20201103,20190423,20201112,EXP,,US-GILEAD-2019-0402590,GILEAD,,36,YR,A,M,Y,68.03,KG,20201112,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood calcium decreased;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;HIV infection;Haematuria;Joint dislocation;Neuropathy peripheral;Pain;Proteinuria;Renal failure;Renal impairment;Vitamin D deficiency,162297476,OT,,,162297476,1,20050323,20161121,,,162297476,1,Acquired immunodeficiency syndrome
16266155,162661555,5,F,201204,20201019,20190502,20201118,EXP,,US-GILEAD-2019-0405401,GILEAD,,29,YR,A,M,Y,68,KG,20201118,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Multiple fractures;Osteonecrosis;Osteoporosis;Pain,162661555,OT,,,162661555,1,200602,201601,,,162661555,1,HIV infection
16266182,162661824,4,F,2006,20201002,20190502,20201006,EXP,,US-GILEAD-2019-0405370,GILEAD,,55,YR,A,M,Y,90.7,KG,20201006,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Lipohypertrophy;Loss of personal independence in daily activities;Osteonecrosis;Pain in extremity;Renal failure,162661824,OT,,,162661824,1,200602,200802,,,162661824,1,HIV infection
16308155,163081553,3,F,,20201020,20190514,20201028,EXP,,CA-ALVOGEN-2019-ALVOGEN-099727,ALVOGEN,,,,N,,Y,,,20201028,,HP,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,163081553,OT,,,,,,,,,163081553,1,Product used for unknown indication
16325325,163253254,4,F,2003,20201201,20190517,20201209,EXP,,US-GILEAD-2019-0407769,GILEAD,,,,A,M,Y,70.3,KG,20201209,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone density decreased;Bone pain;Chronic kidney disease;Economic problem;Emotional distress;Hypercreatininaemia;Osteoarthritis;Osteonecrosis;Pain;Pain in extremity;Renal failure;Renal pain,163253254,OT,,,163253254,1,200305,200409,,,163253254,1,HIV infection
16327418,163274183,3,F,1998,20200818,20190517,20201009,PER,,US-GILEAD-2019-0407762,GILEAD,,53,YR,A,F,Y,86.62,KG,20201009,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood pressure abnormal;Bone density decreased;Bone loss;CD4 lymphocytes abnormal;Depression;Economic problem;Emotional distress;Pain;Pain in extremity;Renal impairment;Wrist fracture,163274183,OT,,,163274183,1,2008,2010,,,163274183,1,HIV infection
16333099,163330992,2,F,200705,20200815,20190520,20201030,EXP,,US-GILEAD-2019-0407826,GILEAD,,49,YR,A,M,Y,99,KG,20201030,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Fear;Foot fracture;General physical health deterioration;Loose tooth;Muscle spasms;Myalgia;Neck pain;Osteoporosis;Pain;Periodontitis;Quality of life decreased;Spinal pain;Tooth fracture;Tooth loss,163330992,OT,,,163330992,1,2006,2016,,,163330992,1,HIV infection
16335806,163358062,2,F,2010,20200815,20190521,20201017,EXP,,US-GILEAD-2019-0408027,GILEAD,,55,YR,A,M,Y,,,20201017,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Fatigue;Osteoporosis;Pain;Renal failure,163358062,OT,,,163358062,1,2011,20190826,,,163358062,1,HIV infection
16338249,163382492,2,F,20120213,20200616,20190521,20201009,EXP,,US-GILEAD-2019-0408272,GILEAD,,50,YR,A,M,Y,62.59,KG,20201009,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Pain,163382492,OT,,,163382492,1,20090705,20120214,,,163382492,1,HIV infection
16349775,163497752,2,F,201408,20200713,20190523,20201009,PER,,US-GILEAD-2019-0408303,GILEAD,,55,YR,A,F,Y,78.01,KG,20201009,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteopenia;Pain,,,,,163497752,1,2005,2010,,,163497752,1,HIV infection
16357029,163570295,5,F,20130311,20200904,20190527,20201005,EXP,,US-GILEAD-2019-0409401,GILEAD,,45,YR,A,M,Y,79.37,KG,20201005,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,163570295,OT,,,163570295,1,20040106,20080514,,,163570295,1,HIV infection
16359867,163598676,6,F,200901,20201019,20190528,20201102,EXP,,US-GILEAD-2019-0409397,GILEAD,,48,YR,A,M,Y,83.9,KG,20201102,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Nightmare;Pain;Suicidal ideation,163598676,OT,,,163598676,1,200901,201001,,,163598676,1,HIV infection
16430786,164307865,5,F,2010,20201117,20190614,20201130,EXP,,US-GILEAD-2019-0413028,GILEAD,,,,A,M,Y,74.83,KG,20201130,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Osteonecrosis;Pain;Post-traumatic stress disorder;Renal cyst;Tooth loss,164307865,OT,,,164307865,1,2005,2010,,,164307865,1,HIV infection
16438510,164385103,3,F,,20200921,20190617,20201006,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106137,VIIV,,,,,M,Y,,,20201006,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,164385103,HO,,,,,,,,,164385103,1,Product used for unknown indication
16438515,164385153,3,F,,20200921,20190617,20201006,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106137,GLAXOSMITHKLINE,,,,,M,Y,,,20201006,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction,164385153,HO,,,,,,,,,164385153,1,Product used for unknown indication
16470789,164707897,7,F,,20201113,20190624,20201123,EXP,,UG-MYLANLABS-2019M1058216,MYLAN,,,,,F,Y,3.7,KG,20201123,,HP,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Congenital skin dimples;Congenital umbilical hernia;Foetal exposure during pregnancy,164707897,CA,,,164707897,1,20170721,20180614,,,164707897,1,HIV infection
16623707,166237075,5,F,20120615,20201103,20190724,20201112,EXP,,US-GILEAD-2019-0419555,GILEAD,,56,YR,A,M,Y,57.2,KG,20201112,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Condition aggravated;Economic problem;Emotional distress;Glomerulonephritis;Haematuria;Intervertebral disc degeneration;Nephropathy;Osteoarthritis;Pain;Proteinuria;Renal cyst;Renal failure,166237075,OT,,,166237075,1,2006,2018,,,166237075,1,HIV infection
16638680,166386805,5,F,,20201113,20190726,20201123,EXP,,UG-MYLANLABS-2019M1069122,MYLAN,,,,,F,Y,,,20201123,,HP,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,166386805,CA,,,166386805,1,20140818,20190524,,,166386805,1,HIV infection
16654245,166542455,5,F,2010,20201019,20190731,20201028,EXP,,US-GILEAD-2019-0420395,GILEAD,,38,YR,A,M,Y,70.3,KG,20201028,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Economic problem;Emotional distress;Osteopenia;Osteoporotic fracture;Pain;Renal failure,166542455,OT,,,166542455,1,200205,201206,,,166542455,1,HIV infection
16765537,167655375,5,F,20131026,20200904,20190903,20201020,EXP,,US-GILEAD-2019-0425749,GILEAD,,51,YR,A,M,Y,74.39,KG,20201020,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Economic problem;Emotional distress;Hand fracture;Pain;Tooth loss,167655375,OT,,,167655375,1,2014,2019,,,167655375,1,HIV infection
16779164,167791645,5,F,201404,20201113,20190906,20201127,EXP,,US-GILEAD-2019-0426574,GILEAD,,47,YR,A,M,Y,108,KG,20201127,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Multiple fractures;Osteonecrosis;Pain;Renal failure,167791645,OT,,,167791645,1,20110609,201404,,,167791645,1,HIV infection
16789078,167890788,8,F,2012,20201106,20190910,20201119,EXP,,US-GILEAD-2019-0426612,GILEAD,,48,YR,A,M,Y,123.36,KG,20201119,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Death;Economic problem;Emotional distress;End stage renal disease;Osteoporosis;Pain;Renal failure,167890788,OT,,,167890788,1,2012,2019,,,167890788,1,HIV infection
16806891,1680689110,10,F,2001,20201103,20190913,20201110,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086812,BRISTOL MYERS SQUIBB,"LOPEZ ASPIROZ E, CABRERA FIGUEROA SE, VALVERDE MERINO MP, CARRACEDO ALVAREZ A. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT. CLINICAL DRUG INVESTIGATION. 2019;39 (11):1125-31",38,YR,,M,Y,,,20201110,,HP,ES,ES,EFAVIRENZ.,Neurotoxicity,1680689110,OT,,,1680689110,1,2001,2001,,,1680689110,1,HIV infection
16818085,168180852,2,F,,20190905,20190917,20201103,EXP,,GB-JNJFOC-20190910701,JOHNSON AND JOHNSON,"OLIVEIRA R, PATEL RK, TAYLOR C, CZUPRYNSKA J, ARYA R, ROBERTS LN. DIRECT ORAL ANTICOAGULANTS FOR THE MANAGEMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH HIV ? A SINGLE CENTRE EXPERIENCE. BRITISH JOURNAL OF HAEMATOLOGY. 2019;186:5:E148-E151",,,A,M,Y,,,20201103,,HP,GB,GB,EFAVIRENZ.,Drug interaction;Embolism venous,168180852,OT,,,,,,,,,168180852,1,Embolism venous
16826328,168263286,6,F,20070215,20200928,20190919,20201013,EXP,,US-GILEAD-2019-0428473,GILEAD,,35,YR,A,M,Y,79.37,KG,20201013,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Depression;Economic problem;Emotional distress;Fanconi syndrome acquired;Femur fracture;Flank pain;Hip arthroplasty;Insomnia;Leukocyturia;Multiple fractures;Nephrolithiasis;Osteoarthritis;Osteomalacia;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Post-traumatic stress disorder;Renal cyst;Renal failure;Rib fracture;Scapula fracture;Sternal fracture;Vitamin D deficiency,168263286,OT,,,168263286,1,20060725,20121203,,,168263286,1,HIV infection
16835292,168352929,9,F,,20201030,20190920,20201106,EXP,,FR-GLAXOSMITHKLINE-FR2019169921,GLAXOSMITHKLINE,,,,,M,Y,3.23,KG,20201106,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168352929,CA,,,168352929,1,20070403,20070521,,,168352929,1,HIV infection
16835297,168352979,9,F,,20201030,20190920,20201106,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2019169921,VIIV,,,,,M,Y,3.23,KG,20201106,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168352979,CA,,,168352979,1,20070403,20070521,,,168352979,1,HIV infection
16837989,168379893,3,F,20051230,20200617,20190923,20201113,EXP,,US-GILEAD-2019-0429311,GILEAD,,37,YR,A,M,Y,104.76,KG,20201113,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal disorder;Renal failure,168379893,OT,,,168379893,1,200111,20060830,,,168379893,1,HIV infection
16844386,168443863,3,F,20160122,20201113,20190924,20201119,EXP,,US-GILEAD-2019-0429662,GILEAD,,60,YR,A,M,Y,72.56,KG,20201119,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Emotional distress;Loss of personal independence in daily activities;Pain;Quality of life decreased,168443863,OT,,,168443863,1,2001,201901,,,168443863,1,HIV infection
16845064,168450643,3,F,2013,20201214,20190924,20201223,EXP,,US-GILEAD-2019-0429307,GILEAD,,,,A,F,Y,45.35,KG,20201223,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure,168450643,OT,,,168450643,1,2008,2013,,,168450643,1,HIV infection
16845626,168456263,3,F,200404,20201220,20190924,20201231,EXP,,US-GILEAD-2019-0429615,GILEAD,,41,YR,A,M,Y,68.03,KG,20201231,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fatigue;Pain;Quality of life decreased;Renal failure;Renal transplant,168456263,OT,,,168456263,1,2001,2017,,,168456263,1,HIV infection
16846009,168460093,3,F,2008,20200814,20190924,20201022,PER,,US-GILEAD-2019-0429346,GILEAD,,30,YR,A,M,Y,105.22,KG,20201022,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Renal transplant,168460093,HO,,,168460093,1,2012,2013,,,168460093,1,HIV infection
16851962,168519623,3,F,200712,20201106,20190925,20201119,EXP,,US-GILEAD-2019-0429428,GILEAD,,45,YR,A,F,Y,54.42,KG,20201119,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Clavicle fracture;Decreased activity;Disturbance in attention;Economic problem;Emotional distress;Fatigue;Femoral neck fracture;Fine motor skill dysfunction;Foot fracture;Forearm fracture;Hip fracture;Loss of employment;Loss of personal independence in daily activities;Mobility decreased;Osteopenia;Osteoporosis;Pain;Personal relationship issue;Quality of life decreased;Renal failure;Rib fracture;Social problem;Upper limb fracture,168519623,OT,,,168519623,1,2003,2015,,,168519623,1,HIV infection
16852781,168527814,4,F,1998,20201110,20190925,20201112,EXP,,US-GILEAD-2019-0429286,GILEAD,,55,YR,A,M,Y,112.93,KG,20201112,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone disorder;Chronic kidney disease-mineral and bone disorder;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased,168527814,OT,,,168527814,1,200908,201403,,,168527814,1,HIV infection
16854370,168543703,3,F,2008,20201028,20190926,20201106,EXP,,US-GILEAD-2019-0429592,GILEAD,,63,YR,A,F,Y,52.15,KG,20201106,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Ankle fracture;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Decreased activity;Economic problem;Emotional distress;Fanconi syndrome acquired;Fatigue;Fear;Foot fracture;Glomerular filtration rate abnormal;Loss of personal independence in daily activities;Mobility decreased;Osteoporosis;Pain;Protein urine present;Quality of life decreased;Rib fracture;Wrist fracture,168543703,OT,,,168543703,1,200405,200907,,,168543703,1,HIV infection
16855625,168556253,3,F,2010,20200914,20190926,20201027,EXP,,US-GILEAD-2019-0429788,GILEAD,,47,YR,A,M,Y,90.7,KG,20201027,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Insomnia;Loss of personal independence in daily activities;Pain;Panic attack;Quality of life decreased;Renal failure;Wheelchair user,168556253,OT,,,168556253,1,2006,2010,,,168556253,1,HIV infection
16855931,168559312,2,F,2016,20200920,20190926,20201005,EXP,,US-GILEAD-2019-0429827,GILEAD,,,,A,M,Y,97.96,KG,20201005,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Decreased activity;Emotional distress;End stage renal disease;Fatigue;Illness;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased;Vomiting,168559312,OT,,,168559312,1,2006,2014,,,168559312,1,HIV infection
16859830,1685983017,17,F,,20201030,20190927,20201106,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-092601,BRISTOL MYERS SQUIBB,,,,,M,Y,3.23,KG,20201106,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,1685983017,CA,,,1685983017,1,20070403,20070510,,,1685983017,1,Product used for unknown indication
16861386,168613862,2,F,2005,20201015,20190927,20201027,EXP,,US-GILEAD-2019-0429649,GILEAD,,45,YR,A,F,Y,,,20201027,,CN,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Bone pain;Economic problem;Emotional distress;Gait disturbance;Hyperkalaemia;Loss of personal independence in daily activities;Lower limb fracture;Osteoporosis;Pain;Quality of life decreased;Renal failure;Renal pain;Suicidal ideation,168613862,OT,,,168613862,1,200408,2017,,,168613862,1,HIV infection
16863042,168630423,3,F,2007,20201109,20190927,20201116,EXP,,US-GILEAD-2019-0429241,GILEAD,,53,YR,A,M,Y,84.81,KG,20201116,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Economic problem;Emotional distress;End stage renal disease;Pain,168630423,DE,,,168630423,1,200607,201606,,,168630423,1,HIV infection
16928945,169289453,3,F,20070403,20201004,20191017,20201012,EXP,,FR-TEVA-2019-FR-1122063,TEVA,,,,N,M,Y,3.23,KG,20201012,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,169289453,CA,,,169289453,1,20070403,20070521,,,169289453,1,HIV infection
16969122,169691225,5,F,20160101,20201202,20191029,20201207,EXP,,US-GILEAD-2019-0434689,GILEAD,,57,YR,A,M,Y,113.38,KG,20201207,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone loss;Depression;Economic problem;Emotional distress;Intervertebral disc degeneration;Liver disorder;Nerve compression;Osteonecrosis;Osteoporosis;Osteoporotic fracture;Pain;Renal disorder,169691225,OT,,,169691225,1,200101,201601,,,169691225,1,HIV infection
17075955,170759556,6,F,2013,20200904,20191126,20201119,EXP,,US-GILEAD-2019-0439498,GILEAD,,55,YR,A,M,Y,70.3,KG,20201119,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Antisocial behaviour;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Foot fracture;Osteoporosis;Pain;Renal failure;Renal tubular necrosis,170759556,HO,,,170759556,1,20130612,20130719,,,170759556,1,HIV infection
17075959,170759596,6,F,20160530,20201109,20191126,20201112,EXP,,US-GILEAD-2019-0439481,GILEAD,,59,YR,A,M,Y,64.85,KG,20201112,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Fracture;Osteoarthritis;Pain;Renal failure;Renal tubular disorder;Tooth loss,170759596,OT,,,170759596,1,200709,20111028,,,170759596,1,HIV infection
17075964,170759646,6,F,201009,20201210,20191126,20201215,EXP,,US-GILEAD-2019-0439491,GILEAD,,53,YR,A,M,Y,52.15,KG,20201215,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Pain;Renal failure,170759646,OT,,,170759646,1,20020823,20101201,,,170759646,1,HIV infection
17086665,170866653,3,F,,20201204,20191128,20201216,EXP,,CA-APOTEX-2018AP015491,APOTEX,,,,,,Y,,,20201216,,CN,CA,CA,EMTRICITABINE/TENOFOVIR/EFAVIRENZ,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,170866653,CA,,,,,,,,,170866653,1,Prophylaxis against HIV infection
17120780,171207806,6,F,2010,20201023,20191206,20201102,EXP,,US-GILEAD-2019-0440919,GILEAD,,57,YR,A,M,Y,72.56,KG,20201102,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Dysstasia;Economic problem;Emotional distress;Forearm fracture;Gait disturbance;Genotype drug resistance test positive;Loss of personal independence in daily activities;Osteonecrosis;Osteopenia;Pain;Tooth fracture;Tooth loss;Viral load abnormal;Wrist fracture,171207806,OT,,,171207806,1,20100316,20110510,,,171207806,1,HIV infection
17148035,171480352,2,F,2008,20201007,20191212,20201020,EXP,,US-GILEAD-2019-0441982,GILEAD,,53,YR,A,M,Y,98,KG,20201020,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Impaired work ability;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal impairment;Renal injury,171480352,OT,,,171480352,1,2008,20110714,,,171480352,1,Product used for unknown indication
17198087,171980873,3,F,,20201106,20191225,20201120,EXP,,CA-ROCHE-2500389,ROCHE,,,,A,M,Y,,,20201120,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,171980873,OT,,,,,,,,,171980873,1,Bipolar disorder
17210299,172102992,2,F,,20201014,20191227,20201028,EXP,,CA-ROCHE-2504654,ROCHE,,54,YR,,M,Y,,,20201028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,172102992,OT,,,,,,,,,172102992,1,Product used for unknown indication
17214260,172142605,5,F,1996,20201123,20191230,20201201,EXP,,ES-MYLANLABS-2019M1127115,MYLAN,"ASPIROZ EL, CABRERA FIGUEROA SE, VALVERDE MERINO MP, ALVAREZ AC.. INDIVIDUALIZED PROTEASE INHIBITOR MONOTHERAPY: THE ROLE OF PHARMACOKINETICS AND PHARMACOGENETICS IN AN AGED AND HEAVILY TREATED HIV-INFECTED PATIENT.. CLINICAL DRUG INVESTIGATION. 2019;39:1125-31",38,YR,,M,Y,,,20201201,,HP,CL,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Bone pain;Chronic kidney disease;Drug abuse;Dyslipidaemia;Fanconi syndrome;Fatigue;Glycosuria;Hypophosphataemia;Intentional product misuse;Lipodystrophy acquired;Medication error;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Nephropathy toxic;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,172142605,OT,,,172142605,1,1997,2001,,,172142605,1,Antiretroviral therapy
17225079,1722507918,18,F,20070403,20201204,20200102,20201218,EXP,,FR-MYLANLABS-2019M1131600,MYLAN,,,,N,M,Y,3.23,KG,20201218,,HP,FR,FR,EFAVIRENZ.;SUSTIVA,Foetal exposure during pregnancy;Hydrocele,1722507918,OT,,,1722507918,1,20070403,20070521,,,1722507918,1,HIV infection
17244308,172443083,3,F,2014,20201112,20200107,20201119,EXP,,US-GILEAD-2019-0444842,GILEAD,,52,YR,A,F,Y,70.3,KG,20201119,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain,172443083,HO,,,172443083,1,20121011,20150409,,,172443083,1,HIV infection
17244332,172443323,3,F,2008,20201203,20200107,20201210,EXP,,US-GILEAD-2019-0444850,GILEAD,,,,A,M,Y,86.17,KG,20201210,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Pain,172443323,OT,,,172443323,1,201002,201204,,,172443323,1,HIV infection
17244336,172443363,3,F,20161103,20201112,20200107,20201119,PER,,US-GILEAD-2019-0444847,GILEAD,,49,YR,A,M,Y,68.93,KG,20201119,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Osteopenia;Pain,,,,,172443363,1,20030819,20060826,,,172443363,1,HIV infection
17244347,172443473,3,F,2012,20201211,20200107,20201223,EXP,,US-GILEAD-2019-0444865,GILEAD,,,,A,M,Y,81.63,KG,20201223,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Gait disturbance;Pain,172443473,OT,,,172443473,1,2003,201510,,,172443473,1,HIV infection
17244437,172444374,4,F,2017,20200902,20200107,20201022,EXP,,US-GILEAD-2019-0444942,GILEAD,,,,A,M,Y,58.5,KG,20201022,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Fracture;Pain;Tooth loss;Wrist fracture,172444374,OT,,,172444374,1,2006,20170731,,,172444374,1,HIV infection
17257723,172577234,4,F,,20201124,20200110,20201202,EXP,,PT-MYLANLABS-2020M1002389,MYLAN,"CERTAL M, CUNHA RG, MOUTINHO A, TAVARES S, GUIMARAES F, MARQUES PV.. HIPOPITUITARISMO EM DOENTE COM CO-INFECCAO PELO VIRUS DA IMUNODEFICIENCIA HUMANA (VIH) TIPO 1 E HEPATITE C (VHC) CRONICA.EPOSTER:DOEN?AS ENDOCRINAS E METABOLICAS.. CONGRESSO NACIONAL DE MEDICINA INTERNA. 2019;23-26",45,YR,,M,Y,,,20201202,,MD,PT,PT,EFAVIRENZ.,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,172577234,HO,,,172577234,2,2010,,,,172577234,1,HIV infection
17291227,172912275,5,F,2007,20201022,20200121,20201027,EXP,,US-GILEAD-2020-0447101,GILEAD,,54,YR,A,M,Y,74.38,KG,20201027,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Fanconi syndrome acquired;Fracture;Hip fracture;Nephrolithiasis;Osteomalacia;Osteopenia;Osteoporotic fracture;Pain;Renal cyst;Tooth loss;Wrist fracture,172912275,OT,,,172912275,1,200510,20060203,,,172912275,1,HIV infection
17313822,173138223,3,F,2014,20201006,20200124,20201016,EXP,,US-GILEAD-2020-0448025,GILEAD,,47,YR,A,M,Y,104.3,KG,20201016,,CN,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Disturbance in attention;Eating disorder;Economic problem;Emotional distress;End stage renal disease;Fatigue;Pain;Renal disorder;Renal failure;Sexual dysfunction;Sleep apnoea syndrome;Sleep disorder,173138223,OT,,,173138223,1,20120209,201601,,,173138223,1,HIV infection
17324065,173240656,6,F,20090909,20201216,20200127,20201218,EXP,,US-GILEAD-2020-0448201,GILEAD,,30,YR,A,F,Y,64.85,KG,20201218,,CN,US,US,SUSTIVA,Acute kidney injury;Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;End stage renal disease;Renal injury,173240656,OT,,,173240656,1,200605,201912,,,173240656,1,HIV infection
17347351,173473513,3,F,2009,20201005,20200130,20201019,EXP,,US-GILEAD-2020-0448787,GILEAD,,34,YR,A,M,Y,65.76,KG,20201019,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain,173473513,OT,,,173473513,1,201407,2016,,,173473513,1,HIV infection
17355530,173555303,3,F,20131005,20201203,20200131,20201210,EXP,,US-GILEAD-2020-0448761,GILEAD,,44,YR,A,M,Y,77.1,KG,20201210,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Apathy;Asthenia;Chronic kidney disease;Depression;Economic problem;Emotional distress;Fatigue;Insomnia;Pain;Social avoidant behaviour,173555303,OT,,,173555303,1,20111213,20140812,,,173555303,1,HIV infection
17364204,1736420419,19,F,20070403,20201201,20200204,20201210,EXP,,FR-AUROBINDO-AUR-APL-2020-004851,AUROBINDO,,7,WK,,M,Y,3.23,KG,20201210,,CN,FR,FR,EFAVIRENZ.;SUSTIVA,Foetal exposure during pregnancy;Hydrocele,1736420419,OT,,,1736420419,1,20070512,20070521,,,1736420419,1,HIV infection
17366674,173666742,2,F,,20201123,20200204,20201201,EXP,,BW-MYLANLABS-2020M1013049,MYLAN,,42,YR,,F,Y,,,20201201,,HP,BW,BW,EFAVIRENZ.,Hydrocephalus;Maternal exposure during pregnancy;Meningomyelocele;Stillbirth,173666742,OT,,,,,,,,,173666742,1,HIV infection
17371124,173711244,4,F,,20201030,20200205,20201110,EXP,,FR-MACLEODS PHARMACEUTICALS US LTD-MAC2020024999,MACLEODS,,,,,,Y,,,20201110,,HP,US,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,173711244,CA,,,173711244,1,20070403,20070521,,,173711244,1,Product used for unknown indication
17375978,173759783,3,F,,20201123,20200206,20201126,EXP,,BW-AUROBINDO-AUR-APL-2020-005963,AUROBINDO,,,,,,Y,,,20201126,,MD,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Stillbirth,173759783,CA,,,,,,,,,173759783,1,Product used for unknown indication
17484391,174843916,6,F,200909,20201215,20200302,20201223,EXP,,US-GILEAD-2020-0452915,GILEAD,,51,YR,A,M,Y,88.44,KG,20201223,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Condition aggravated;Economic problem;Emotional distress;Fear of falling;Loss of personal independence in daily activities;Nephrolithiasis;Osteopenia;Osteoporosis;Pain;Physical disability;Renal impairment;Tooth fracture;Tooth loss,174843916,OT,,,174843916,1,20090225,20100809,,,174843916,1,HIV infection
17497526,174975266,6,F,2006,20201123,20200304,20201204,EXP,,US-GILEAD-2020-0452918,GILEAD,,42,YR,A,M,Y,70.75,KG,20201204,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Glomerulonephritis chronic;Pain;Renal failure;Renal tubular necrosis,174975266,OT,,,174975266,1,2006,201808,,,174975266,1,HIV infection
17510565,175105652,2,F,201901,20200904,20200306,20201002,EXP,,US-GILEAD-2020-0453649,GILEAD,,,,,M,Y,75.74,KG,20201002,,LW,US,US,SUSTIVA,Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175105652,HO,,,175105652,1,20130920,20190227,,,175105652,1,HIV infection
17523420,175234204,4,F,20161220,20201023,20200310,20201103,EXP,,US-GILEAD-2020-0454098,GILEAD,,55,YR,A,M,Y,72.56,KG,20201103,,LW,US,US,SUSTIVA,Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Pain;Renal failure,175234204,OT,,,175234204,1,20090824,20141119,,,175234204,1,HIV infection
17533091,175330915,5,F,200908,20201008,20200312,20201015,EXP,,US-GILEAD-2020-0454085,GILEAD,,47,YR,A,M,Y,101.13,KG,20201015,,LW,US,US,SUSTIVA,Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Nephrotic syndrome;Pain;Renal failure,175330915,OT,,,175330915,1,20090402,201001,,,175330915,1,HIV infection
17570438,175704383,3,F,201101,20200904,20200323,20201002,EXP,,US-GILEAD-2020-0455808,GILEAD,,69,YR,E,M,Y,74,KG,20201002,,CN,US,US,SUSTIVA,Bone density decreased;Bone loss;Economic problem;Emotional distress;Fracture;Hip fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Tooth loss,175704383,OT,,,175704383,1,200701,20190913,,,175704383,1,HIV infection
17571419,175714192,2,F,2010,20200831,20200323,20201017,EXP,,US-GILEAD-2020-0455859,GILEAD,,,,A,M,Y,55.33,KG,20201017,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Tooth loss,175714192,OT,,,175714192,1,20080107,201712,,,175714192,1,HIV infection
17572240,175722402,2,F,2004,20201209,20200323,20201222,EXP,,US-GILEAD-2020-0455887,GILEAD,,,,A,M,Y,79.37,KG,20201222,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone density decreased;Depression;Economic problem;Emotional distress;Foot fracture;Loss of personal independence in daily activities;Osteopenia;Osteoporosis;Pain;Sciatica,175722402,OT,,,175722402,1,200206,20021125,,,175722402,1,HIV infection
17575487,175754872,2,F,2015,20201109,20200324,20201120,EXP,,US-GILEAD-2020-0455884,GILEAD,,,,A,M,Y,94.79,KG,20201120,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Osteopenia;Pain,175754872,OT,,,175754872,1,2006,2018,,,175754872,1,HIV infection
17577194,175771944,4,F,201411,20201206,20200324,20201210,EXP,,US-GILEAD-2020-0455942,GILEAD,,63,YR,A,M,Y,90.7,KG,20201210,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Nephrolithiasis;Osteopenia;Pain,175771944,OT,,,175771944,1,20070427,2014,,,175771944,1,HIV infection
17579166,175791663,3,F,2008,20201113,20200325,20201125,PER,,US-GILEAD-2020-0456141,GILEAD,,46,YR,A,M,Y,81.63,KG,20201125,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Clavicle fracture;Depression;Economic problem;Emotional distress;Gout;Pain;Rib fracture;Wrist fracture,175791663,OT,,,175791663,1,2004,2018,,,175791663,1,HIV infection
17600360,176003608,8,F,,20201005,20200330,20201009,EXP,,FR-MYLANLABS-2020M1032592,MYLAN,,1,DY,,,Y,,,20201009,,CN,US,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,176003608,CA,,,,,,,,,176003608,1,HIV infection
17732671,177326713,3,F,,20201019,20200501,20201102,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK074404,VIIV,,54,YR,,M,Y,,,20201102,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,177326713,OT,,,,,,,,,177326713,1,Bipolar disorder
17732677,177326773,3,F,,20201019,20200501,20201102,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK074404,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20201102,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,177326773,OT,,,,,,,,,177326773,1,Bipolar disorder
17743771,177437712,2,F,,20201019,20200505,20201102,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK075602,VIIV,,54,YR,,M,Y,,,20201102,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,177437712,OT,,,,,,,,,177437712,1,Bipolar disorder
17743782,177437822,2,F,,20201019,20200505,20201102,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK075602,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20201102,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,177437822,OT,,,,,,,,,177437822,1,Bipolar disorder
17772651,177726512,2,F,201810,20201211,20200512,20201223,EXP,,US-GILEAD-2020-0466109,GILEAD,,56,YR,A,F,Y,,,20201223,,CN,US,US,SUSTIVA,Multiple fractures;Osteoporosis;Renal injury;Skeletal injury,177726512,OT,,,177726512,1,2004,,,,177726512,1,HIV infection
17904644,179046446,6,F,20020111,20201123,20200617,20201207,EXP,,US-GILEAD-2020-0471554,GILEAD,,65,YR,E,M,Y,88.44,KG,20201207,,LW,US,US,SUSTIVA,Blood creatinine increased;Chronic kidney disease;Drug ineffective;Fanconi syndrome acquired;Lumbar vertebral fracture;Multiple fractures;Nephropathy;Radiculopathy;Renal failure;Viral load increased,179046446,OT,,,179046446,1,20020111,20050525,,,179046446,1,HIV infection
17916100,179161004,4,F,201412,20201005,20200619,20201015,EXP,,US-GILEAD-2020-0473594,GILEAD,,67,YR,E,F,Y,58.96,KG,20201015,,CN,US,US,SUSTIVA,Anhedonia;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Fracture;Hip arthroplasty;Hip fracture;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Pathological fracture;Proteinuria;Stress fracture,179161004,OT,,,179161004,1,2009,2019,,,179161004,1,HIV infection
17949727,179497274,4,F,,20200930,20200626,20201008,EXP,E2B_02966351,CA-ACCORD-186554,ACCORD,,54,YR,,M,Y,,,20201008,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,179497274,OT,,,,,,,,,179497274,1,Bipolar disorder
17982291,179822914,4,F,,20201130,20200706,20201205,EXP,,FR-AUROBINDO-AUR-APL-2020-032078,AUROBINDO,,,,I,,Y,,,20201205,,CN,FR,FR,Efavirenz Film Coated Tablets,Foetal exposure during pregnancy;Pachygyria,179822914,OT,,,,,,,,,179822914,1,Product used for unknown indication
18051609,180516092,2,F,,20200708,20200721,20201007,EXP,,LV-GLAXOSMITHKLINE-LV2020EME125104,GLAXOSMITHKLINE,,45,YR,,F,Y,,,20201007,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,180516092,OT,,,180516092,1,2015,,,,180516092,1,HIV infection
18051610,180516102,2,F,,20200708,20200721,20201007,EXP,,LV-VIIV HEALTHCARE LIMITED-LV2020EME125104,VIIV,,45,YR,,F,Y,,,20201007,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,180516102,OT,,,180516102,1,2015,,,,180516102,1,HIV infection
18055939,180559394,4,F,200002,20201217,20200722,20201230,PER,,US-GILEAD-2020-0484456,GILEAD,,58,YR,A,M,Y,84.81,KG,20201230,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Bone density decreased;Depression;Drug ineffective;Emotional distress;Fatigue;Genotype drug resistance test positive;Osteoporosis;Pain;Rib fracture,180559394,OT,,,180559394,1,2001,2010,,,180559394,1,HIV infection
18058168,180581685,5,F,,20201222,20200723,20201231,EXP,,FR-AUROBINDO-AUR-APL-2020-036053,AUROBINDO,,1,DY,,,Y,,,20201231,,HP,FR,FR,Efavirenz Film Coated Tablets,Cerebral ventricle dilatation;Foetal exposure during pregnancy;Pachygyria;White matter lesion,180581685,CA,,,,,,,,,180581685,1,HIV infection
18065982,180659823,3,F,2019,20201009,20200724,20201014,EXP,,LV-ABBVIE-20K-287-3495672-00,ABBVIE,,45,YR,,F,Y,,,20201014,,MD,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Hyperhidrosis;Live birth;Maternal exposure during pregnancy,180659823,OT,,,180659823,1,2015,,,,180659823,1,HIV infection
18068131,180681312,2,F,2009,20200929,20200724,20201005,EXP,,US-GILEAD-2020-0485178,GILEAD,,,,A,F,Y,142.86,KG,20201005,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Depression;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Osteoporosis;Pain,180681312,OT,,,180681312,1,2001,201605,,,180681312,1,HIV infection
18068866,180688662,2,F,2013,20201013,20200724,20201022,PER,,US-GILEAD-2020-0485048,GILEAD,,,,A,M,Y,86.18,KG,20201022,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Renal impairment,,,,,180688662,1,2008,2016,,,180688662,1,HIV infection
18077162,180771622,2,F,,20201123,20200728,20201130,EXP,,FR-HETERO-HET2020FR00834,HETERO,,,,I,,Y,,,20201130,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,180771622,CA,,,,,,,,,180771622,1,HIV infection
18077288,180772882,2,F,2014,20201116,20200727,20201120,EXP,,US-GILEAD-2020-0485109,GILEAD,,,,A,M,Y,63.49,KG,20201120,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteonecrosis;Osteoporosis;Pain;Renal failure;Renal impairment,180772882,OT,,,180772882,1,2005,2018,,,180772882,1,HIV infection
18080758,180807583,3,F,201811,20200928,20200728,20201016,EXP,,US-GILEAD-2020-0485140,GILEAD,,55,YR,A,F,Y,81.63,KG,20201016,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Osteoporosis;Pain,180807583,OT,,,180807583,1,2007,2016,,,180807583,1,HIV infection
18105627,181056274,4,F,2015,20201019,20200803,20201023,EXP,,LV-MYLANLABS-2020M1068298,MYLAN,,45,YR,,F,Y,,,20201023,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,181056274,OT,,,181056274,1,2019,,,,181056274,1,HIV infection
18109437,181094373,3,F,20101014,20200901,20200804,20201008,EXP,,US-GILEAD-2020-0486792,GILEAD,,59,YR,A,F,Y,49,KG,20201008,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Depression;Emotional distress;Glomerular filtration rate decreased;Hand fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain;Proteinuria;Renal failure,181094373,HO,,,181094373,1,20050401,20160914,,,181094373,1,HIV infection
18110954,181109542,2,F,2014,20200724,20200804,20201210,EXP,,US-GILEAD-2020-0488466,GILEAD,,,,A,F,Y,55.78,KG,20201210,,CN,US,US,SUSTIVA,Chronic kidney disease;Emotional distress;End stage renal disease;Pain;Renal failure,181109542,HO,,,181109542,1,201011,201212,,,181109542,1,HIV infection
18111305,181113053,3,F,2015,20201015,20200804,20201020,EXP,,LV-009507513-2007LVA010997,MERCK,,45,YR,,F,Y,,,20201020,,CN,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,181113053,OT,,,181113053,1,2015,,,,181113053,1,HIV infection
18116834,181168342,2,F,,20201123,20200806,20201128,EXP,,US-ABBVIE-20K-163-3511165-00,ABBVIE,,,,,M,Y,3.24,KG,20201128,,HP,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,181168342,CA,,,,,,,,,181168342,1,Maternal exposure timing unspecified
18129721,181297212,2,F,2016,20201019,20200810,20201102,EXP,,US-GILEAD-2020-0488477,GILEAD,,44,YR,A,M,Y,,,20201102,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Depression;Emotional distress;Hepatic function abnormal;Pain;Renal impairment,181297212,OT,,,181297212,1,2001,2016,,,181297212,1,HIV infection
18133418,181334182,2,F,20010322,20200805,20200811,20201028,EXP,,US-VIIV HEALTHCARE LIMITED-A0147188A,VIIV,,0,DY,,M,Y,3.2,KG,20201028,,CN,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,181334182,OT,,,181334182,2,20001109,20000926,,,181334182,1,HIV infection
18133525,181335252,2,F,20010322,20200805,20200811,20201028,EXP,,US-GLAXOSMITHKLINE-A0147188A,GLAXOSMITHKLINE,,0,DY,,M,Y,3.2,KG,20201028,,CN,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,181335252,OT,,,181335252,2,20001109,20000926,,,181335252,1,HIV infection
18142329,181423292,2,F,2011,20201006,20200812,20201017,EXP,,US-GILEAD-2020-0489724,GILEAD,,50,YR,A,M,Y,68.03,KG,20201017,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Osteopenia;Osteoporosis;Pain;Spinal fracture,181423292,OT,,,181423292,1,200712,201612,,,181423292,1,HIV infection
18147382,181473823,3,F,201301,20201203,20200813,20201214,PER,,US-GILEAD-2020-0489260,GILEAD,,41,YR,A,M,Y,111.11,KG,20201214,,CN,US,US,EFAVIRENZ.;EFAVIRENZ;EMTRICITABINE;TENOFOVIR;SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Emotional distress;Pain;Renal impairment,181473823,OT,,,181473823,1,2001,201607,,,181473823,1,HIV infection
18148773,181487733,3,F,201407,20201013,20200813,20201028,EXP,,US-GILEAD-2020-0489270,GILEAD,,60,YR,A,M,Y,88.44,KG,20201028,,LW,US,US,EFAVIRENZ.;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Emotional distress;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Spinal compression fracture,181487733,OT,,,181487733,1,2009,20160914,,,181487733,1,HIV infection
18158157,181581572,2,F,20141126,20200914,20200817,20201007,EXP,,US-GILEAD-2020-0489417,GILEAD,,51,YR,A,M,Y,123.36,KG,20201007,,LW,US,US,SUSTIVA,Acute kidney injury;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Osteoporosis;Pain,181581572,OT,,,181581572,1,2001,2020,,,181581572,1,HIV infection
18158162,181581623,3,F,200706,20200930,20200817,20201116,EXP,,US-GILEAD-2020-0489414,GILEAD,,43,YR,A,M,Y,,,20201116,,CN,US,US,EFAVIRENZ.,Anxiety;Chronic kidney disease;Emotional distress;Pain,181581623,OT,,,181581623,1,2009,201001,,,181581623,1,HIV infection
18158198,181581982,2,F,2012,20201005,20200817,20201019,EXP,,US-GILEAD-2020-0489363,GILEAD,,55,YR,A,F,Y,75.28,KG,20201019,,LW,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;Chronic kidney disease;Emotional distress;Femur fracture;Gait disturbance;Hip fracture;Lower limb fracture;Mental impairment;Osteoporosis;Pain,181581982,HO,,,181581982,1,2003,20131115,,,181581982,1,HIV infection
18158634,181586343,3,F,20050425,20201125,20200817,20201203,PER,,US-GILEAD-2020-0489335,GILEAD,,59,YR,A,F,Y,45.35,KG,20201203,,CN,US,US,EFAVIRENZ.;SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Emotional distress;Multiple fractures;Osteoporosis;Pain,181586343,HO,,,181586343,1,200609,20161107,,,181586343,1,HIV infection
18160753,181607533,3,F,2013,20201217,20200817,20201230,PER,,US-GILEAD-2020-0489852,GILEAD,,,,A,M,Y,97.51,KG,20201230,,CN,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Multiple fractures;Pain;Renal impairment,181607533,OT,,,181607533,1,20120828,20120919,,,181607533,1,HIV infection
18163556,181635562,2,F,2015,20200911,20200818,20201008,PER,,US-GILEAD-2020-0490410,GILEAD,,52,YR,A,M,Y,72.56,KG,20201008,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Drug ineffective;Emotional distress;Myalgia;Pain;Pain in extremity,181635562,OT,,,181635562,1,2004,20181016,,,181635562,1,HIV infection
18163710,181637104,4,F,2008,20200918,20200818,20201016,EXP,,US-GILEAD-2020-0490419,GILEAD,,,,A,M,Y,81.63,KG,20201016,,LW,US,US,SUSTIVA,Bone density decreased;Emotional distress;Foot fracture;Osteoporosis;Pain,181637104,OT,,,181637104,1,2004,2008,,,181637104,1,HIV infection
18164238,181642382,2,F,2005,20201002,20200818,20201009,EXP,,US-GILEAD-2020-0490115,GILEAD,,,,A,M,Y,61.22,KG,20201009,,LW,US,US,SUSTIVA,Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain;Renal impairment,181642382,OT,,,181642382,1,2004,20111214,,,181642382,1,HIV infection
18166711,181667112,2,F,2013,20201005,20200819,20201016,EXP,,US-GILEAD-2020-0490497,GILEAD,,,,,,Y,,,20201016,,CN,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Emotional distress;Osteoporosis;Pain;Renal impairment,181667112,OT,,,181667112,1,2011,,,,181667112,1,HIV infection
18168897,181688972,2,F,2005,20201012,20200818,20201017,EXP,,US-GILEAD-2020-0490418,GILEAD,,,,A,M,Y,112,KG,20201017,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Cervical vertebral fracture;Emotional distress;Lumbar vertebral fracture;Osteoporosis;Pain;Renal impairment,181688972,OT,,,181688972,1,2004,20190827,,,181688972,1,HIV infection
18168943,181689433,3,F,2009,20201118,20200818,20201126,EXP,,US-GILEAD-2020-0489652,GILEAD,,,,A,M,Y,58.96,KG,20201126,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Blood creatinine increased;Bone density decreased;Emotional distress;Hip fracture;Osteoporosis;Pain;Protein urine present;Renal impairment;Wrist fracture,181689433,OT,,,181689433,1,2006,20190617,,,181689433,1,HIV infection
18170718,181707183,3,F,20160729,20201202,20200819,20201209,EXP,,US-GILEAD-2020-0489845,GILEAD,,50,YR,A,M,Y,98.87,KG,20201209,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain;Renal failure,181707183,OT,,,181707183,1,201504,201607,,,181707183,1,HIV infection
18170885,181708852,2,F,20170116,20201007,20200819,20201018,EXP,,US-GILEAD-2020-0490137,GILEAD,,63,YR,A,M,Y,53.52,KG,20201018,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Osteoporosis;Pain;Renal impairment,181708852,OT,,,181708852,1,2006,20150527,,,181708852,1,HIV infection
18171201,181712012,2,F,2006,20200914,20200819,20201002,EXP,,US-GILEAD-2020-0489986,GILEAD,,,,A,M,Y,70.3,KG,20201002,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,181712012,OT,,,181712012,1,2003,2006,,,181712012,1,Product used for unknown indication
18171264,181712643,3,F,201601,20201218,20200819,20201229,EXP,,US-GILEAD-2020-0490139,GILEAD,,54,YR,A,M,Y,114.29,KG,20201229,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Multiple fractures;Osteoporosis;Pain;Tooth loss,181712643,OT,,,181712643,1,2004,2008,,,181712643,1,HIV infection
18172099,181720992,2,F,2008,20201001,20200819,20201006,EXP,,US-GILEAD-2020-0490269,GILEAD,,,,A,F,Y,104.31,KG,20201005,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Gout;Pain,181720992,OT,,,181720992,1,2007,2018,,,181720992,1,HIV infection
18172920,181729204,4,F,2016,20201204,20200820,20201217,EXP,,US-GILEAD-2020-0490188,GILEAD,,63,YR,A,M,Y,81.63,KG,20201217,,CN,US,US,SUSTIVA,Abdominal distension;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Dysstasia;Emotional distress;Gait disturbance;Multiple fractures;Pain,181729204,OT,,,181729204,1,2001,2004,,,181729204,1,HIV infection
18172968,181729682,2,F,200812,20201016,20200819,20201028,EXP,,US-GILEAD-2020-0490120,GILEAD,,31,YR,A,M,Y,145,KG,20201028,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteoporosis;Pain,181729682,OT,,,181729682,1,200608,201710,,,181729682,1,HIV infection
18172978,181729783,3,F,2005,20201211,20200819,20201223,EXP,,US-GILEAD-2020-0490072,GILEAD,,56,YR,A,M,Y,78.46,KG,20201223,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Nightmare;Pain,181729783,OT,,,181729783,1,200211,201706,,,181729783,1,HIV infection
18176940,181769403,3,F,201411,20201016,20200820,20201022,EXP,,US-GILEAD-2020-0489895,GILEAD,,50,YR,A,F,Y,70.75,KG,20201022,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density abnormal;Chronic kidney disease;Emotional distress;Osteopenia;Pain;Product use complaint;Wrist fracture,181769403,HO,,,181769403,1,201008,201410,,,181769403,1,HIV infection
18178260,181782602,2,F,2019,20201016,20200821,20201029,PER,,US-GILEAD-2020-0491252,GILEAD,,64,YR,,M,Y,73.92,KG,20201029,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone pain;Depression;Emotional distress;Fear of falling;Hepatic function abnormal;Injury;Loss of personal independence in daily activities;Osteopenia;Pain,,,,,181782602,1,2004,201901,,,181782602,1,HIV infection
18178893,181788933,3,F,20171213,20201202,20200820,20201209,EXP,,US-GILEAD-2020-0489901,GILEAD,,56,YR,A,F,Y,88.44,KG,20201209,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Back pain;Chronic kidney disease;Depression;Emotional distress;Fatigue;Loss of personal independence in daily activities;Pain;Peripheral swelling;Pollakiuria;Renal tubular necrosis,181788933,OT,,,181788933,1,201510,201807,,,181788933,1,HIV infection
18179409,181794093,3,F,,20201215,20200821,20201225,EXP,,CA-ROCHE-2583896,ROCHE,,52,YR,,M,Y,,,20201225,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,181794093,OT,,,,,,,,,181794093,1,HIV infection
18179440,181794404,4,F,20091216,20201016,20200820,20201119,EXP,,US-GILEAD-2020-0489859,GILEAD,,44,YR,A,M,Y,115,KG,20201119,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Drug resistance;Economic problem;Emotional distress;Osteopenia;Pain,181794404,OT,,,181794404,1,200403,200409,,,181794404,1,HIV infection
18180472,181804724,4,F,,20201123,20200821,20201204,EXP,,"FR-LANNETT COMPANY, INC.-FR-2020LAN000198",LANNETT,,,,I,M,Y,3.23,KG,20201204,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,181804724,OT,,,,,,,,,181804724,1,Product used for unknown indication
18181094,181810942,2,F,2002,20201103,20200821,20201111,PER,,US-GILEAD-2020-0491031,GILEAD,,,,A,F,Y,90.7,KG,20201111,,CN,US,US,SUSTIVA,Anxiety;Blood creatinine increased;Depression;Emotional distress;Nephropathy;Pain,,,,,181810942,1,20090612,20100217,,,181810942,1,HIV infection
18182871,181828713,3,F,20070918,20200916,20200821,20201007,PER,,US-GILEAD-2020-0489938,GILEAD,,33,YR,A,M,Y,98.87,KG,20201007,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Pain;Renal impairment;Renal injury,181828713,OT,,,181828713,1,2004,2007,,,181828713,1,HIV infection
18184143,181841432,2,F,2008,20200929,20200823,20201011,EXP,,US-GILEAD-2020-0491100,GILEAD,,,,A,M,Y,96.15,KG,20201011,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Fracture;Osteoporosis;Pain;Renal impairment,181841432,OT,,,181841432,1,2004,2018,,,181841432,1,HIV infection
18193939,181939392,2,F,201406,20201125,20200825,20201207,EXP,,US-GILEAD-2020-0491422,GILEAD,,66,YR,E,M,Y,73.47,KG,20201207,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Chronic kidney disease;Emotional distress;Loss of personal independence in daily activities;Pain,181939392,OT,,,181939392,1,200406,201710,,,181939392,1,HIV infection
18199815,181998152,2,F,2015,20201123,20200826,20201202,EXP,,US-GILEAD-2020-0491171,GILEAD,,,,A,F,Y,79.37,KG,20201202,,CN,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Depression;Emotional distress;Fanconi syndrome acquired;Osteopenia;Pain;Renal disorder;Renal tubular dysfunction,181998152,OT,,,181998152,1,201304,201409,,,181998152,1,HIV infection
18213241,182132412,2,F,2015,20201019,20200831,20201029,EXP,,LV-TEVA-2020-LV-1820060,TEVA,,45,YR,A,F,Y,,,20201029,,MD,LV,LV,EFAVIRENZ.,Blood HIV RNA increased;Drug resistance;Exposure during pregnancy;Hyperhidrosis;Therapy change,182132412,OT,,,182132412,1,2015,,,,182132412,1,HIV infection
18215147,182151474,4,F,201009,20201111,20200831,20201118,PER,,US-GILEAD-2020-0491163,GILEAD,,60,YR,A,M,Y,95.24,KG,20201118,,CN,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;Depression;Fatigue;Hypoaesthesia;Osteopenia,182151474,OT,,,182151474,1,200506,201506,,,182151474,1,HIV infection
18217383,182173833,3,F,,20201009,20200901,20201015,EXP,,GB-ADVANZ PHARMA-202008008318,ADVANZ PHARMA,,,,,,Y,,,20201015,,HP,GB,GB,EFAVIRENZ.,Cataract;Osteoporotic fracture;Steroid diabetes;Urinary tract infection,182173833,OT,,,182173833,2,2009,,,,182173833,1,Immune reconstitution inflammatory syndrome associated tuberculosis
18235457,182354572,2,F,,20201123,20200905,20201126,EXP,,BW-AUROBINDO-AUR-APL-2020-046931,AUROBINDO,,42,YR,,F,Y,,,20201126,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,182354572,OT,,,,,,,,,182354572,1,Product used for unknown indication
18254327,182543272,2,F,2020,20200925,20200910,20201008,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-073154,BRISTOL MYERS SQUIBB,,64,YR,,M,Y,,,20201008,,MD,FR,FR,EFAVIRENZ.,Acute kidney injury;Bone pain;Fanconi syndrome acquired,182543272,OT,,,182543272,1,20110323,20200823,,,182543272,1,HIV infection
18261156,182611562,2,F,2020,20200925,20200914,20201003,EXP,,FR-AUROBINDO-AUR-APL-2020-047348,AUROBINDO,,64,YR,,M,Y,,,20201003,,MD,FR,FR,EFAVIRENZ.,Acute kidney injury;Bone pain;Fanconi syndrome,182611562,OT,,,182611562,1,20110323,20200823,,,182611562,1,HIV infection
18284305,182843052,2,F,,20200929,20200918,20201001,EXP,,ID-GILEAD-2020-0495222,GILEAD,"SUFIAWATI I., MASKOEN A, SOEMANTRI E.. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE. ORAL DISEASES. 2020;26 (1):165-168. DOI:10.1111/ODI.13403",,,N,F,Y,,,20201001,,MD,ID,ID,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Gene mutation,182843052,OT,,,,,,,,,182843052,1,HIV infection
18301827,183018272,2,F,,20200929,20200923,20201005,EXP,,ID-VIIV HEALTHCARE LIMITED-ID2020GSK184896,VIIV,"SUFIAWATI I, MASKOEN AM, SOEMANTRI ESS. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE. ORAL DISEASES. 2020;26(S1):165-168",,,,F,Y,,,20201005,,HP,ID,ID,SUSTIVA,Cleft lip and palate;Foetal exposure during pregnancy;Gene mutation;HIV infection;Vertical infection transmission,183018272,CA,,,,,,,,,183018272,1,HIV infection
18301831,183018312,2,F,,20200929,20200923,20201005,EXP,,ID-GLAXOSMITHKLINE-ID2020GSK184896,GLAXOSMITHKLINE,"SUFIAWATI I, MASKOEN AM, SOEMANTRI ESS. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE. ORAL DISEASES. 2020;26(S1):165-168",,,,F,Y,,,20201005,,HP,ID,ID,SUSTIVA,Cleft lip and palate;Foetal exposure during pregnancy;Gene mutation;HIV infection;Vertical infection transmission,183018312,CA,,,,,,,,,183018312,1,HIV infection
18303995,183039952,2,F,,20200930,20200924,20201001,EXP,,US-TEVA-2020-US-1829772,TEVA,"SHALLIS RM, GLEESON S, AZAR MM, MALINIS M, XU ML, SEROPIAN SE, ET AL. ALLOGENEIC STEM CELL TRANSPLANTATION AND COMBINATION ANTIRETROVIRAL THERAPY: CAUTIONS, COMPLICATIONS, AND CONSIDERATIONS. LEUK-LYMPHOMA 2019;60(10):2584-2587.",44,YR,A,F,Y,,,20201001,,HP,US,US,Efavirenz/emtricitabine/tenofovir disoproxil fumarate,Drug ineffective;Myelodysplastic syndrome;Thrombocytopenia,183039952,HO,,,,,,,,,183039952,1,B-cell lymphoma
18314835,183148352,2,F,2020,20201006,20200926,20201014,EXP,FR-AFSSAPS-NT20201194,FR-TEVA-2020-FR-1830959,TEVA,,64,YR,A,M,Y,,,20201014,,MD,FR,FR,EFAVIRENZ.,Acute kidney injury;Bone pain;Fanconi syndrome,183148352,HO,,,183148352,1,20110323,20200823,,,183148352,1,HIV infection
18317941,183179412,2,F,,20201013,20200928,20201023,EXP,,ID-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-076938,BRISTOL MYERS SQUIBB,"SUFIAWATI I, MASKOEN AM, SOEMANTRI ESS. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PLATE. ORAL DISEASES. 2020;26(SUPPL 1):165-8",1,DY,,F,Y,,,20201023,,HP,ID,ID,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Gene mutation,183179412,OT,,,,,,,,,183179412,1,Product used for unknown indication
18332754,183327541,1,I,200909,20200917,20201001,20201001,EXP,,ZA-LUPIN PHARMACEUTICALS INC.-2020-06616,LUPIN,,40,YR,,F,Y,,,20201001,,HP,ZA,ZA,EFAVIRENZ.,Drug interaction;Drug resistance;Pathogen resistance;Virologic failure,183327541,OT,,,183327541,1,2007,20091224,,,183327541,1,Antiretroviral therapy
18336200,183362001,1,I,,20200503,20201001,20201001,EXP,,CA-TEVA-2020-CA-1233155,TEVA,,54,YR,A,M,Y,,,20201001,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183362001,OT,,,,,,,,,183362001,1,Product used for unknown indication
18336818,183368182,2,F,,20201029,20201001,20201105,EXP,,CA-009507513-1902CAN006433,MERCK,,44,YR,,M,Y,,,20201105,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,183368182,HO,,,,,,,,,183368182,1,HIV infection
18339119,183391191,1,I,,20200925,20201002,20201002,EXP,,ID-MYLANLABS-2020M1083731,MYLAN,"SUFIAWATI I, MASKOEN AM, SOEMANTRI ESS. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE. ORAL-DIS 2020;26(1):165-168.",,,,F,Y,,,20201002,,HP,ID,ID,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy,183391191,CA,,,,,,,,,183391191,1,HIV infection
18343370,183433701,1,I,,20200922,20201005,20201005,EXP,,ZA-CIPLA LTD.-2020ZA07004,CIPLA,,,,,,Y,,,20201005,,HP,ZA,ZA,EFAVIRENZ.,Nephropathy,183433701,HO,,,,,,,,,183433701,1,HIV infection
18343711,183437111,1,I,,20200930,20201005,20201005,EXP,,ID-STRIDES ARCOLAB LIMITED-2020SP011920,STRIDES,"SUFIAWATI I, MASKOEN AM, SOEMANTRI ESS.. GENETIC VARIATION OF IRF6 AND TGFA GENES IN AN HIV-EXPOSED NEWBORN WITH NON-SYNDROMIC CLEFT LIP PALATE.. ORAL DISEASES. 2020;26(1):165-168",,,,F,Y,,,20201005,,HP,ID,ID,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy,183437111,CA,,,,,,,,,183437111,1,Product used for unknown indication
18345487,183454871,1,I,,20201001,20201005,20201005,EXP,,US-GILEAD-2020-0497380,GILEAD,,61,YR,A,F,Y,,,20201005,,CN,US,US,EFAVIRENZ.,Disease progression,183454871,OT,,,183454871,1,20200825,,,,183454871,1,Non-Hodgkin's lymphoma
18346421,183464211,1,I,,20160903,20201006,20201006,EXP,,GB-AUROBINDO-AUR-APL-2016-11730,AUROBINDO,,25,YR,,M,Y,,,20201006,,HP,GB,GB,EFAVIRENZ.,"Abdominal pain lower;Abdominal tenderness;Chromaturia;Constipation;Hallucinations, mixed;Pain;Porphyria acute;Vomiting",183464211,OT,,,,,,,,,183464211,1,HIV infection
18347003,183470031,1,I,,20200928,20201006,20201006,EXP,,US-AUROBINDO-AUR-APL-2020-050001,AUROBINDO,,25,YR,,M,Y,,,20201006,,HP,US,US,EFAVIRENZ.,"Hallucination, visual;Psychotic disorder",183470031,OT,,,,,,,,,183470031,1,HIV infection
18347682,183476821,1,I,,20200928,20201006,20201006,EXP,,GB-AUROBINDO-AUR-APL-2020-050359,AUROBINDO,,,,,,Y,,,20201006,,HP,GB,GB,EFAVIRENZ.,Neurotoxicity,183476821,OT,,,,,,,,,183476821,1,Product used for unknown indication
18348022,183480222,2,F,,20201016,20201006,20201029,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2020028268,MACLEODS,,,,,,Y,,,20201029,,CN,IN,IN,EFAVIRENZ.,Anaemia;Fanconi syndrome acquired;Femur fracture;General physical health deterioration;Renal failure;Sepsis,183480222,OT,,,183480222,1,201408,2019,,,183480222,1,Antiretroviral therapy
18349036,183490361,1,I,,20181017,20201006,20201006,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK189276,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20201006,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490361,OT,,,,,,,,,183490361,1,HIV infection
18349038,183490381,1,I,,20181017,20201006,20201006,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK189276,VIIV,,54,YR,,M,Y,,,20201006,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490381,OT,,,,,,,,,183490381,1,HIV infection
18349183,183491831,1,I,,20200921,20201006,20201006,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK194170,VIIV,,54,YR,,M,Y,,,20201006,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,183491831,OT,,,,,,,,,183491831,1,Product used for unknown indication
18349187,183491871,1,I,,20200921,20201006,20201006,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK194170,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20201006,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,183491871,OT,,,,,,,,,183491871,1,Product used for unknown indication
18349618,183496181,1,I,,20200921,20201006,20201006,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK194023,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20201006,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183496181,OT,,,,,,,,,183496181,1,Bipolar disorder
18349627,183496271,1,I,,20200921,20201006,20201006,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK194023,VIIV,,54,YR,,M,Y,,,20201006,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183496271,OT,,,,,,,,,183496271,1,Bipolar disorder
18352863,183528631,1,I,,20200928,20201007,20201007,EXP,,US-AUROBINDO-AUR-APL-2020-050201,AUROBINDO,,,,,F,Y,,,20201007,,MD,US,US,EFAVIRENZ.,Autoimmune hepatitis;Toxicity to various agents,183528631,OT,,,,,,,,,183528631,1,HIV infection
18357718,183577182,2,F,,20201005,20201008,20201013,EXP,,ES-AUROBINDO-AUR-APL-2020-051068,AUROBINDO,,47,YR,,M,Y,,,20201013,,HP,ES,ES,EFAVIRENZ.,Bipolar disorder;Delirium;Mania;Psychiatric decompensation;Psychotic disorder;Psychotic symptom,183577182,OT,,,,,,,,,183577182,1,HIV infection
18358719,183587191,1,I,,20200925,20201008,20201008,EXP,,ID-LUPIN PHARMACEUTICALS INC.-2020-06920,LUPIN,,,,,F,Y,,,20201008,,HP,ID,ID,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy,183587191,OT,,,,,,,,,183587191,1,HIV infection
18362028,183620281,1,I,,20201005,20201008,20201008,EXP,,FR-MYLANLABS-2020M1084803,MYLAN,,,,I,F,Y,,,20201008,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,183620281,CA,,,,,,,,,183620281,1,Product used for unknown indication
18385419,183854191,1,I,,20200917,20201015,20201015,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-076820,BRISTOL MYERS SQUIBB,,56,YR,,M,Y,,,20201015,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain,,,,,183854191,1,20040315,2008,,,183854191,1,HIV infection
18387262,183872622,2,F,2016,20201204,20201015,20201216,EXP,,US-GILEAD-2020-0498473,GILEAD,,,,A,M,Y,,,20201216,,CN,US,US,SUSTIVA,Bone density decreased;Osteopenia;Osteoporosis;Spinal disorder;Spinal stenosis;Tooth loss,183872622,OT,,,183872622,1,2006,2016,,,183872622,1,HIV infection
18398990,183989901,1,I,,20201009,20201019,20201019,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-084173,BRISTOL MYERS SQUIBB,,70,YR,,M,Y,,,20201019,,MD,AU,AU,EFAVIRENZ.,Acute cardiac event;Drug ineffective,183989901,OT,,,,,,,,,183989901,1,Product used for unknown indication
18400800,184008001,1,I,,20201008,20201019,20201019,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-083848,BRISTOL MYERS SQUIBB,"PATEL R, CASTLES R, RAYMENT M, BARBER T. AN AUDIT OF THERAPEUTIC DRUG MONITORING (TDM) IN CLINICAL PRACTICE. HIV MEDICINE. 2014;15 SUPPL 3:123",,,,,Y,,,20201019,,HP,GB,GB,EFAVIRENZ.,Neurotoxicity,184008001,OT,,,,,,,,,184008001,1,Product used for unknown indication
18405930,184059303,3,F,,20201118,20201020,20201124,EXP,,ES-MYLANLABS-2020M1087834,MYLAN,,47,YR,,M,Y,,,20201124,,HP,ES,ES,EFAVIRENZ.,"Atrophy;Bipolar disorder;Central nervous system lesion;Delirium;Delusional perception;Hallucination, auditory;Insomnia;Mania;Psychiatric decompensation;Psychotic behaviour;Psychotic disorder;Psychotic symptom;Suicidal ideation",184059303,HO,,,,,,,,,184059303,1,HIV infection
18412028,184120281,1,I,,20201015,20201021,20201021,EXP,,US-GILEAD-2020-0500156,GILEAD,,,,,F,Y,,,20201021,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatic cirrhosis;Mental disorder;Product use issue,184120281,OT,,,184120281,1,200611,201111,,,184120281,1,HIV infection
18412888,184128881,1,I,201408,20201012,20201022,20201022,EXP,,IN-CIPLA LTD.-2020IN07585,CIPLA,,,,,,Y,,,20201022,,HP,IN,IN,EFAVIRENZ.,Anaemia;Fanconi syndrome;Femur fracture;Pathological fracture,184128881,HO,,,184128881,1,201408,201408,,,184128881,1,HIV infection
18415398,184153981,1,I,,20201015,20201022,20201022,EXP,,US-GILEAD-2020-0500374,GILEAD,,,,A,M,Y,,,20201022,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density abnormal;Fatigue;Inflammation;Lower limb fracture,184153981,OT,,,,,,,,,184153981,1,HIV infection
18416441,184164411,1,I,,20201019,20201022,20201022,EXP,,GB-MYLANLABS-2020M1088658,MYLAN,EFAVIRENZ CNS TOXICITY. CASE REPORT. 2015,,,,,Y,,,20201022,,HP,GB,GB,EFAVIRENZ.,Neurotoxicity,184164411,OT,,,,,,,,,184164411,1,Product used for unknown indication
18420531,184205311,1,I,2007,20201012,20201023,20201023,EXP,,US-GILEAD-2020-0499315,GILEAD,,64,YR,A,M,Y,113.38,KG,20201023,,CN,US,US,SUSTIVA,Acute kidney injury;Back pain;Bone density decreased;Chronic kidney disease;Decreased activity;Depression;Emotional distress;Pain;Post-traumatic stress disorder;Renal impairment,184205311,HO,,,184205311,1,20070822,20110507,,,184205311,1,HIV infection
18422750,184227501,1,I,,20201013,20201023,20201023,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020GSK205570,VIIV,"WEN Y, WANG MC, ZHOU Y, LIN XY, HOU G, YIN Y. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH PNEUMOCYSTIS PNEUMONIA IN A PATIENT WITH AIDS. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. 2020;48(8)",21,YR,,M,Y,,,20201023,,HP,CN,CN,EFAVIRENZ.,Chills;Condition aggravated;Disease recurrence;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Lung consolidation;Nausea;Pneumocystis jirovecii pneumonia;Pneumonitis;Pyrexia;Respiratory failure;White blood cell count increased,184227501,OT,,,,,,,,,184227501,1,HIV infection
18422751,184227511,1,I,,20201013,20201023,20201023,EXP,,CN-GLAXOSMITHKLINE-CN2020GSK205570,GLAXOSMITHKLINE,"WEN Y, WANG MC, ZHOU Y, LIN XY, HOU G, YIN Y. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH PNEUMOCYSTIS PNEUMONIA IN A PATIENT WITH AIDS. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. 2020;48(8)",21,YR,,M,Y,,,20201023,,HP,CN,CN,EFAVIRENZ.,Chills;Condition aggravated;Disease recurrence;Immune reconstitution inflammatory syndrome;Interstitial lung disease;Lung consolidation;Nausea;Pneumocystis jirovecii pneumonia;Pneumonitis;Pyrexia;Respiratory failure;White blood cell count increased,184227511,OT,,,,,,,,,184227511,1,HIV infection
18425641,184256411,1,I,201808,20201015,20201026,20201026,EXP,FR-AFSSAPS-PB20200898,FR-TEVA-2020-FR-1840584,TEVA,,38,YR,A,F,Y,,,20201024,,MD,FR,FR,EFAVIRENZ EMTRICITABINE TENOFOVIR DISOPROXIL TEVA,Dermatitis bullous;Product dispensing error,184256411,OT,,,184256411,1,201808,201902,,,184256411,1,Hepatitis
18428002,184280021,1,I,,20201019,20201026,20201026,EXP,,CN-GILEAD-2020-0500441,GILEAD,"WEN Y, WANG MC, ZHOU Y, LIN XY, HOU G, YIN Y. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH PNEUMOCYSTIS PNEUMONIA IN A PATIENT WITH AIDS. J INT MED RES.. 2020;48(8):1-6. DOI:10.1177/0300060520946544",21,YR,A,M,Y,,,20201026,,MD,CN,CN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,184280021,OT,,,,,,,,,184280021,1,HIV infection
18428121,184281212,2,F,,20201020,20201026,20201124,EXP,,IN-MYLANLABS-2020M1089993,MYLAN,,45,YR,,F,Y,,,20201124,,HP,IN,IN,EFAVIRENZ.,Anaemia;Fanconi syndrome acquired;Femur fracture;Renal disorder;Renal failure,184281212,OT,,,184281212,1,201404,201408,,,184281212,1,HIV infection
18428348,184283481,1,I,,20201019,20201026,20201026,EXP,,IN-GILEAD-2020-0500543,GILEAD,"DALAL P, ANOT K, MONICA G, D?CRUZ S. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. J NEUROVIROL.. 2020;26(5):793-796. DOI:10.1007/S13365-020-00879-4",35,YR,A,M,Y,,,20201026,,MD,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome,184283481,HO,,,,,,,,,184283481,1,HIV infection
18429117,184291171,1,I,,20201019,20201026,20201026,EXP,,CA-BAUSCH-BL-2020-030676,BAUSCH AND LOMB,,54,YR,,M,Y,,,20201026,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,184291171,OT,,,,,,,,,184291171,1,Bipolar disorder
18429118,184291181,1,I,,20201019,20201026,20201026,EXP,,CA-BAUSCH-BL-2020-030678,BAUSCH AND LOMB,,54,YR,,M,Y,,,20201026,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,184291181,OT,,,,,,,,,184291181,1,Bipolar disorder
18429140,184291401,1,I,,20201016,20201027,20201027,EXP,,IN-HETERO-HET2020IN01158,HETERO,,45,YR,,F,Y,,,20201027,,HP,IN,IN,EFAVIRENZ.,Fanconi syndrome acquired;Femur fracture;Renal failure,184291401,DE,,,184291401,1,201408,2019,,,184291401,1,Antiretroviral therapy
18429327,184293271,1,I,,20201017,20201027,20201027,EXP,,ES-AUROBINDO-AUR-APL-2020-053584,AUROBINDO,,52,YR,,M,Y,,,20201027,,HP,ES,ES,EFAVIRENZ.,"Atrophy;Central nervous system lesion;Delusional perception;Hallucination, auditory;Insomnia;Mania;Psychotic behaviour;Suicidal ideation",184293271,HO,,,,,,,,,184293271,1,HIV infection
18431007,184310071,1,I,201909,20201016,20201027,20201027,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-086717,BRISTOL MYERS SQUIBB,,48,YR,,F,Y,,,20201027,,MD,PT,PT,EFAVIRENZ.,Acute myocardial infarction;Blood cholesterol increased;Disease risk factor;Left ventricular dysfunction;Lipodystrophy acquired;Viral load decreased,184310071,OT,,,184310071,1,2007,,,,184310071,1,Product used for unknown indication
18433520,184335201,1,I,2017,20201014,20201027,20201027,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK208216,GLAXOSMITHKLINE,"PRABHU V, COELHO S, ACHAPPA B, BALIGA S, SHARON L, SHAH J. ROLE OF FLUORESCENCE IN SITU HYBRIDIZATION IN DETECTING MYCOBACTERIUM AVIUM COMPLEX PRESENTING AS FEVER IN TREATMENT FAILURE HIV. JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES. 2020;21",49,YR,,M,Y,,,20201027,,HP,IN,IN,EFAVIRENZ.,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;CD4 lymphocytes decreased;Candida infection;Chills;Dysphagia;Erosive duodenitis;Gastrooesophageal reflux disease;Granulomatous liver disease;Granulomatous lymphadenitis;HIV infection;Hepatomegaly;Hypochromic anaemia;Lymphadenitis bacterial;Lymphadenopathy;Lymphocytosis;Mycobacterium avium complex infection;Oesophageal ulcer;Oesophagitis;Oropharyngeal pain;Pharyngeal ulceration;Pyrexia;Splenomegaly;Thrombocytopenia;Treatment noncompliance;Vomiting,184335201,HO,,,184335201,1,,2017,,,184335201,1,HIV infection
18433646,184336461,1,I,2017,20201014,20201027,20201027,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK208216,VIIV,"PRABHU V, COELHO S, ACHAPPA B, BALIGA S, SHARON L, SHAH J. ROLE OF FLUORESCENCE IN SITU HYBRIDIZATION IN DETECTING MYCOBACTERIUM AVIUM COMPLEX PRESENTING AS FEVER IN TREATMENT FAILURE HIV. JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES. 2020;21",49,YR,,M,Y,,,20201027,,HP,IN,IN,EFAVIRENZ.,Abdominal pain;Alanine aminotransferase increased;Aspartate aminotransferase increased;CD4 lymphocytes decreased;Candida infection;Chills;Dysphagia;Erosive duodenitis;Gastrooesophageal reflux disease;Granulomatous liver disease;Granulomatous lymphadenitis;HIV infection;Hepatomegaly;Hypochromic anaemia;Lymphadenitis bacterial;Lymphadenopathy;Lymphocytosis;Mycobacterium avium complex infection;Oesophageal ulcer;Oesophagitis;Oropharyngeal pain;Pharyngeal ulceration;Pyrexia;Splenomegaly;Thrombocytopenia;Treatment noncompliance;Vomiting,184336461,HO,,,184336461,1,,2017,,,184336461,1,HIV infection
18435228,184352281,1,I,199809,20201022,20201028,20201028,EXP,,IT-ROCHE-2701861,ROCHE,"ORTU F, WEIMER LE, FLORIDIA M, MANCONI PE. RALTEGAVIR, TENOFOVIR, AND EMTRICITABINE IN AN HIV INFECTED PATIENT WITH HCV CHRONIC HEPATITIS, NNRTI INTOLERANCE AND PROTEASE INHIBITORS INDUCED SEVERE LIVER TOXICITY. EUROPEAN JOURNAL OF MEDICAL RESEARCH. 2010;15:81-83.",,,A,F,Y,,,20201028,,HP,IT,IT,EFAVIRENZ.,Hepatotoxicity;Nausea;Nephrolithiasis;Neurological symptom;Rash;Vomiting,184352281,OT,,,184352281,5,200210,,,,184352281,1,Antiretroviral therapy
18435451,184354511,1,I,,20201019,20201028,20201028,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP012702,STRIDES,"SEN P, SUDHARSHAN S, BANERJEE A, DHAMI A.. CLINICAL AND ELECTROPHYSIOLOGICAL CHARACTERISTICS OF EFAVIRENZ-INDUCED MACULAR TOXICITY.. GMS OPHTHAMOL CASES.. 2020;10:2193-1496",54,YR,,F,Y,,,20201028,,MD,IN,IN,EFAVIRENZ.,Vision blurred;Visual field defect,184354511,OT,,,,,,,,,184354511,1,HIV infection
18441543,184415431,1,I,20201007,20201021,20201029,20201029,EXP,,US-GILEAD-2020-0500587,GILEAD,,48,YR,A,M,Y,,,20201029,,PH,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nephrolithiasis;Product use issue,184415431,OT,,,184415431,1,,20201007,,,184415431,1,HIV infection
18444919,184449191,1,I,,20201016,20201030,20201030,EXP,,CL-GLAXOSMITHKLINE-CL2020GSK215217,GLAXOSMITHKLINE,,,,,,Y,,,20201030,,HP,CL,CL,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,184449191,OT,,,,,,,,,184449191,1,HIV infection
18444965,184449651,1,I,,20201016,20201030,20201030,EXP,,CL-VIIV HEALTHCARE LIMITED-CL2020GSK215217,VIIV,,,,,,Y,,,20201030,,HP,CL,CL,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,184449651,OT,,,,,,,,,184449651,1,HIV infection
18445873,184458731,1,I,,20201022,20201030,20201030,EXP,,IN-MYLANLABS-2020M1090972,MYLAN,,35,YR,,M,Y,,,20201030,,MD,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myelitis transverse;Paraparesis,184458731,HO,,,,,,,,,184458731,1,HIV infection
18449904,184499042,2,F,,20201125,20201102,20201208,EXP,,IN-LUPIN PHARMACEUTICALS INC.-2020-08008,LUPIN,,45,YR,,F,Y,,,20201208,,HP,IN,IN,EFAVIRENZ.,Fanconi syndrome acquired;Femur fracture;General physical health deterioration;Renal disorder;Renal failure,184499042,DE,,,184499042,1,201404,201408,,,184499042,1,HIV infection
18452184,184521841,1,I,,20201019,20201102,20201102,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK209280,GLAXOSMITHKLINE,"DALAL P, ANOT K, MONICA G, D^CRUZ S. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. JOURNAL OF NEUROVIROLOGY. 2020;26 (5):793-796",35,YR,,M,Y,,,20201102,,MD,IN,IN,EFAVIRENZ.,Abdominal discomfort;Areflexia;Central nervous system immune reconstitution inflammatory response;Hyperintensity in brain deep nuclei;Hypoaesthesia;Hypotonia;Muscular weakness;Myelitis transverse;Paraparesis;Sensory disturbance;Spinal pain;Urinary retention,184521841,HO,,,,,,,,,184521841,1,HIV infection
18452546,184525461,1,I,,20201019,20201102,20201102,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK209280,VIIV,"DALAL P, ANOT K, MONICA G, D^CRUZ S. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. JOURNAL OF NEUROVIROLOGY. 2020;26 (5):793-796",35,YR,,M,Y,,,20201102,,MD,IN,IN,EFAVIRENZ.,Abdominal discomfort;Areflexia;Central nervous system immune reconstitution inflammatory response;Hyperintensity in brain deep nuclei;Hypoaesthesia;Hypotonia;Muscular weakness;Myelitis transverse;Paraparesis;Sensory disturbance;Spinal pain;Urinary retention,184525461,HO,,,,,,,,,184525461,1,HIV infection
18452791,184527914,4,F,,20201120,20201102,20201202,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-089390,BRISTOL MYERS SQUIBB,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV: DATA FROM A LONDON COHORT. JOURNAL OF VIRUS ERADICATION. 2019;5(1):44-6",28,YR,,F,Y,,,20201202,,HP,GB,GB,EFAVIRENZ.,Off label use;Ovarian failure,184527914,OT,,,184527914,1,1997,,,,184527914,1,Antiretroviral therapy
18455645,184556451,1,I,,20201020,20201103,20201103,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-04899,HIKMA,"ROLL G, POSSELT A, FREISE J, BAIRD J, SYED S, KANG S, HIROSE R, SZOT G, ZARINSEFAT A, FENG S, WORNER G, SARWAL M, STOCK P. LONG-TERM FOLLOW-UP OF BETA CELL REPLACEMENT THERAPY IN 10 HIV-INFECTED PATIENTS WITH RENAL FAILURE SECONDARY TO TYPE 1 DIABETES MELLITUS. AMERICAN JOURNAL OF TRANSPLANTATION. 2020;20 (8):2091-2100.",40,YR,,M,Y,68,KG,20201030,,,COUNTRY NOT SPECIFIED,US,EFAVIRENZ.,Melaena,184556451,OT,,,,,,,,,184556451,1,Pancreas transplant
18455790,184557901,1,I,,20201020,20201103,20201103,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-20-04900,HIKMA,"ROLL G, POSSELT A, FREISE J, BAIRD J, SYED S, KANG S, HIROSE R, SZOT G, ZARINSEFAT A, FENG S, WORNER G, SARWAL M, STOCK P. LONG-TERM FOLLOW-UP OF BETA CELL REPLACEMENT THERAPY IN 10 HIV-INFECTED PATIENTS WITH RENAL FAILURE SECONDARY TO TYPE 1 DIABETES MELLITUS. AMERICAN JOURNAL OF TRANSPLANTATION. 2020;20 (8):2091-2100. DOI:HTTPS://DOI.ORG/10.1111/AJT.15796",32,YR,,M,Y,76.7,KG,20201103,,,COUNTRY NOT SPECIFIED,US,EFAVIRENZ.,BK virus infection;Squamous cell carcinoma;Urinary tract infection,184557901,OT,,,,,,,,,184557901,1,Pancreas transplant
18456605,184566052,2,F,,20201023,20201103,20201106,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP013136,STRIDES,"RAJNISH RK, RATHOD PM, AGGARWAL S, AGARWAL S, KUMAR P.. BILATERAL SUB-TROCHANTERIC FEMUR FRAGILITY FRACTURES IN A PATIENT ON ANTIRETROVIRAL THERAPY: A CASE BASED DISCUSSION AND REVIEW OF LITERATURE. INTERNATIONAL JOURNAL OF BURNS AND TRAUMA. 2020;10(4):121-126",,,A,M,Y,,,20201106,,HP,IN,IN,EFAVIRENZ.,Arthralgia;Fall;Fanconi syndrome;Femur fracture;Osteoporosis;Renal failure;Tenderness;Weight bearing difficulty,184566052,HO,,,184566052,1,201404,201408,,,184566052,1,HIV infection
18457282,184572821,1,I,,20201029,20201103,20201103,EXP,,CA-009507513-2010CAN012011,MERCK,,54,YR,,M,Y,,,20201103,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,184572821,OT,,,,,,,,,184572821,1,HIV infection
18459805,184598051,1,I,,20201029,20201103,20201103,EXP,,CA-009507513-2010CAN012169,MERCK,,54,YR,,M,Y,,,20201103,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,184598051,OT,,,,,,,,,184598051,1,HIV infection
18461736,184617361,1,I,2020,20201023,20201104,20201104,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-08304,LUPIN,,76,YR,,F,Y,,,20201104,,MD,US,US,EFAVIRENZ.,Off label use,184617361,DE,,,184617361,1,2020,2020,,,184617361,1,COVID-19
18462213,184622131,1,I,,20201026,20201104,20201104,EXP,,IT-MYLANLABS-2020M1092154,MYLAN,,,,,,Y,,,20201104,,HP,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood HIV RNA increased;Virologic failure,184622131,OT,,,,,,,,,184622131,1,HIV infection
18462253,184622531,1,I,,20201022,20201104,20201104,EXP,,IN-LUPIN PHARMACEUTICALS INC.-2020-08139,LUPIN,,35,YR,,M,Y,,,20201104,,HP,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myelitis transverse;Paraparesis,184622531,OT,,,,,,,,,184622531,1,HIV infection
18462532,184625321,1,I,,20201027,20201104,20201104,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP013171,STRIDES,"DALAL P, ANOT K, MONICA G, D^CRUZ S.. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY.. JOURNAL OF NEUROVIROLOGY.. 2020;26 (5):793-796",35,YR,,M,Y,,,20201104,,HP,IN,IN,EFAVIRENZ.,Areflexia;Hypoaesthesia;Hypotonia;Immune reconstitution inflammatory syndrome;Muscle tightness;Muscular weakness;Myelitis transverse;Paraesthesia;Paraparesis;Urinary retention,184625321,HO,,,,,,,,,184625321,1,HIV infection
18463020,184630201,1,I,,20201021,20201104,20201104,EXP,,IN-MACLEODS PHARMA UK LTD-MAC2020028841,MACLEODS,,,,,,Y,,,20201104,,MD,IN,IN,EFAVIRENZ.,Depressive symptom;Sedation;Therapy non-responder,184630201,OT,,,,,,,,,184630201,1,Bipolar disorder
18467979,184679791,1,I,,20201028,20201105,20201105,EXP,,CM-MYLANLABS-2020M1092284,MYLAN,"FOKAM J, TAKOU D, SEMENGUE ENJ, TETO G, BELOUMOU G, DAMBAYA B, ET AL. FIRST CASE OF DOLUTEGRAVIR AND DARUNAVIR/R MULTI DRUG-RESISTANT HIV-1 IN CAMEROON FOLLOWING EXPOSURE TO RALTEGRAVIR: LESSONS AND IMPLICATIONS IN THE ERA OF TRANSITION TO DOLUTEGRAVIR-BASED REGIMENS. ANTIMICROB-RESIST-INFECT-CONTROL 2020;9(1):143.",,,A,M,Y,,,20201105,,HP,CM,CM,EFAVIRENZ.,Drug resistance,184679791,OT,,,184679791,1,201711,201905,,,184679791,1,HIV infection
18468672,184686721,1,I,20180822,20201101,20201105,20201105,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2020GSK216742,VIIV,,41,YR,,F,Y,,,20201105,,MD,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,184686721,OT,,,184686721,1,20171204,20180814,,,184686721,1,HIV infection
18472503,184725031,1,I,,20201023,20201106,20201106,EXP,,GB-AUROBINDO-AUR-APL-2020-054025,AUROBINDO,EFAVIRENZ/LAMIVUDINE/TENOFOVIR-MULTICENTRIC CASTLEMAN^S DISEASE AND ACQUIRED ANGIOEDEMA IN THE CONTEXT OF IRIS: CASE REPORT. 2015,37,YR,,F,Y,,,20201106,,HP,GB,GB,EFAVIRENZ.,Angioedema;Castleman's disease;Immune reconstitution inflammatory syndrome,184725031,OT,,,184725031,1,200403,,,,184725031,1,Genital herpes
18473058,184730581,1,I,,20201030,20201106,20201106,EXP,,GB-MYLANLABS-2020M1092865,MYLAN,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV: DATA FROM A LONDON COHORT. J-VIRUS-ERAD 2019;5(1):44-46.",,,,F,Y,,,20201106,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Infertility;Ovarian failure,184730581,OT,,,184730581,1,1997,,,,184730581,1,Perinatal HIV infection
18474173,184741731,1,I,199809,20201102,20201106,20201106,EXP,,IT-MYLANLABS-2020M1093096,MYLAN,"ORTU F, WEIMER LE, FLORIDIA M, MANCONI PE.. RALTEGAVIR, TENOFOVIR, AND EMTRICITABINE IN AN HIV INFECTED PATIENT WITH HCV CHRONIC HEPATITIS, NNRTI INTOLERANCE AND PROTEASE INHIBITORS INDUCED SEVERE LIVER TOXICITY.. EUR. J. MED. RES.. 2010;15:81-3",,,A,F,Y,,,20201106,,HP,IT,IT,EFAVIRENZ.,Hepatotoxicity;Nausea;Nephrolithiasis;Neurological symptom;Rash;Vomiting,184741731,OT,,,184741731,1,199806,,,,184741731,1,Antiretroviral therapy
18479981,184799812,2,F,,20201113,20201109,20201120,EXP,,IT-ROCHE-2707400,ROCHE,"ALFANO G, GIARONI F, FONTANA F, NERI L, OSCONI G, MUSSINI C, GUARALDI G AND CAPPELLI G. RITUXIMAB IN PEOPLE LIVING WITH HIV AFFECTED BY IMMUNE-MEDIATED RENAL DISEASES: A CASE SERIES. INTERNATIONAL JOURNAL OF STD + AIDS 2020 OCT 26;:1-6.",65,YR,,F,Y,,,20201120,,HP,IT,IT,EFAVIRENZ.,CD4 lymphocytes decreased;CD8 lymphocytes decreased;Intentional product use issue;Leukopenia;Neutropenia;Off label use;Pneumonia bacterial,184799812,HO,,,184799812,1,201707,,,,184799812,1,Glomerulonephritis membranous
18486497,184864971,1,I,,20201104,20201110,20201110,EXP,,CA-ASTRAZENECA-2020SF45143,ASTRAZENECA,,54,YR,,M,Y,,,20201110,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,184864971,OT,,,,,,,,,184864971,1,Bipolar disorder
18486507,184865071,1,I,2019,20201101,20201110,20201110,EXP,,PT-GILEAD-2020-0503472,GILEAD,,29,YR,A,M,Y,,,20201110,,MD,PT,PT,EFAVIRENZ.,Acne;Aggression;Anaemia;Anxiety;Dizziness;Dyslipidaemia;Gynaecomastia;Helicobacter gastritis;Hepatocellular injury;Hypersomnia;Hypertension;Insomnia;Polydipsia;Polyuria;Sleep disorder;Treatment noncompliance;Upper gastrointestinal haemorrhage,184865071,OT,,,184865071,1,202006,202006,,,184865071,1,HIV infection
18487330,184873301,1,I,2004,20201031,20201110,20201110,EXP,,PT-009507513-2011PRT001972,MERCK,,21,YR,,M,Y,,,20201110,,MD,PT,PT,EFAVIRENZ.,Alcoholism;Drug resistance;Myocardial infarction;Pancreatitis acute;Pathogen resistance;Treatment noncompliance,184873301,HO,,,184873301,1,2002,2004,,,184873301,16,Chronic hepatitis C
18487650,184876504,4,F,20201027,20201216,20201111,20201216,EXP,,CN-GILEAD-2020-0503255,GILEAD,,,,A,M,Y,80,KG,20201216,,HP,CN,CN,TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAVIRENZ,Drug eruption;Pneumonia,184876504,HO,,,184876504,1,20201014,20201027,,,184876504,1,HIV infection
18487660,184876601,1,I,,20201028,20201111,20201111,EXP,,CM-LUPIN PHARMACEUTICALS INC.-2020-08527,LUPIN,,65,YR,,M,Y,,,20201111,,HP,CM,CM,EFAVIRENZ.,Drug resistance,184876601,OT,,,184876601,1,200608,200708,,,184876601,1,HIV infection
18489274,184892741,1,I,,20201103,20201111,20201111,EXP,,IN-AUROBINDO-AUR-APL-2020-055875,AUROBINDO,,35,YR,,M,Y,,,20201111,,HP,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myelitis transverse;Paraparesis,184892741,OT,,,,,,,,,184892741,1,HIV infection
18495438,184954381,1,I,,20201104,20201112,20201112,EXP,,CA-ASTRAZENECA-2020SF45204,ASTRAZENECA,,54,YR,,M,Y,,,20201112,,HP,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,184954381,OT,,,,,,,,,184954381,1,Bipolar disorder
18498108,184981081,1,I,,20201102,20201112,20201112,EXP,,IN-HETERO-HET2020IN01233,HETERO,"DALAL P, ANOT K, MONICA G, D^CRUZ S.. ACUTE PARAPARESIS IN HIV-INFECTED PATIENT AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY.. J-NEUROVIROL. 2020;26(5):793-796",35,YR,,M,Y,,,20201113,,HP,IN,IN,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myelitis transverse,184981081,OT,,,,,,,,,184981081,1,HIV infection
18498381,184983811,1,I,,20201109,20201113,20201113,EXP,,FR-ABBVIE-20K-056-3643688-00,ABBVIE,,,,N,M,Y,3.23,KG,20201112,,CN,US,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,184983811,OT,,,184983811,7,20070512,,,,184983811,1,Maternal exposure timing unspecified
18499093,184990932,2,F,20200831,20201111,20201112,20201120,EXP,,TH-GILEAD-2020-0502294,GILEAD,,,,A,F,Y,49.8,KG,20201120,,HP,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,False labour;Maternal exposure during pregnancy,184990932,HO,,,184990932,1,20200831,20201106,,,184990932,1,HIV infection
18503485,185034852,2,F,,20201130,20201114,20201211,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-08818,LUPIN,,27,YR,,F,Y,,,20201211,,HP,US,US,EFAVIRENZ.,Ectopic pregnancy;Exposure during pregnancy,185034852,OT,,,,,,,,,185034852,1,HIV infection
18503545,185035451,1,I,,20201103,20201114,20201114,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-08816,LUPIN,,25,YR,,F,Y,,,20201114,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,185035451,OT,,,,,,,,,185035451,1,HIV infection
18503570,185035701,1,I,,20201103,20201114,20201114,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-08823,LUPIN,,23,YR,,F,Y,,,20201114,,HP,US,US,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,185035701,OT,,,,,,,,,185035701,1,HIV infection
18504764,185047641,1,I,,20201103,20201115,20201115,EXP,,US-LUPIN PHARMACEUTICALS INC.-2020-09033,LUPIN,,,,N,,Y,2.1,KG,20201115,,HP,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;Low birth weight baby;Premature baby,185047641,OT,,,,,,,,,185047641,1,HIV infection
18504886,185048863,3,F,,20201203,20201115,20201214,EXP,,GB-AUROBINDO-AUR-APL-2020-056000,AUROBINDO,,28,YR,,F,Y,,,20201214,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Depression;Drug resistance;Failure to thrive;Infertility;Lipodystrophy acquired;Off label use;Ovarian disorder;Ovarian failure;Portal hypertension;Treatment noncompliance,185048863,OT,,,185048863,1,1997,,,,185048863,1,Antiretroviral therapy
18505238,185052381,1,I,2004,20201112,20201116,20201116,EXP,,PT-ABBVIE-20K-130-3649009-00,ABBVIE,,21,YR,,M,Y,,,20201116,,MD,PT,PT,EFAVIRENZ.,Alcoholism;Drug resistance;Myocardial infarction;Pancreatitis acute;Pathogen resistance;Treatment noncompliance,185052381,HO,,,185052381,1,2004,200105,,,185052381,1,Product used for unknown indication
18509237,185092371,1,I,201909,20201104,20201117,20201117,EXP,,CN-CIPLA LTD.-2020CN08704,CIPLA,,,,,,Y,,,20201117,,HP,CN,CN,EFAVIRENZ.,Dermatitis allergic,185092371,OT,,,185092371,1,20190915,201909,,,185092371,1,HIV infection
18509915,185099151,1,I,,20201110,20201117,20201117,EXP,,FR-GILEAD-2020-0504313,GILEAD,,54,YR,A,M,Y,,,20201117,,CN,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acetabulum fracture;Amnesia;Arthritis;Osteoporosis;Pain;Rib fracture;Scoliosis,185099151,OT,,,185099151,1,2009,,,,185099151,1,HIV infection
18510039,185100392,2,F,,20201120,20201117,20201125,EXP,,IT-PFIZER INC-2020449099,PFIZER,"TASCINI, C.. BREAKTHROUGH FUSARIUM SP PROBABLE PNEUMONIA DURING FLUCONAZOLE THERAPY IN AN AIDS PATIENT WITH DIABETES, CANDIDEMIA, PNEUMOCYSTIS CARINII PNEUMONIA AND CYTOMEGALOVIRUS DISSEMINATED INFECTION. JOURNAL OF CHEMOTHERAPY. 2006;18 (2):227-228",56,YR,,M,Y,,,20201125,,HP,IT,IT,EFAVIRENZ.,Drug ineffective;Pathogen resistance,185100392,DE,,,,,,,,,185100392,1,Fungaemia
18514093,185140931,1,I,,20201105,20201118,20201118,EXP,,US-CIPLA LTD.-2020ZM08732,CIPLA,"NAVIS A, DALLAH I, MABETA C, MUSUKUMA K, SIDDIQI OK, BOSITIS CM ET AL.. EVALUATING THE IMPACT OF ANTIRETROVIRAL AND ANTISEIZURE MEDICATION INTERACTIONS ON TREATMENT EFFECTIVENESS AMONG OUTPATIENT CLINIC ATTENDEES WITH HIV IN ZAMBIA. EPILEPSIA. 2020;00:1 TO 7",,,,,Y,,,20201118,,HP,US,ZM,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Drug interaction;Drug resistance;Virologic failure,185140931,OT,,,,,,,,,185140931,1,HIV infection
18514534,185145341,1,I,,20201105,20201118,20201118,EXP,,ZM-CIPLA LTD.-2020ZM08731,CIPLA,"NAVIS A, DALLAH I, MABETA C, MUSUKUMA K, SIDDIQI OK, BOSITIS CM ET AL.. EVALUATING THE IMPACT OF ANTIRETROVIRAL AND ANTISEIZURE MEDICATION INTERACTIONS ON TREATMENT EFFECTIVENESS AMONG OUTPATIENT CLINIC ATTENDEES WITH HIV IN ZAMBIA. EPILEPSIA. 2020;00:1 TO 7",,,,,Y,,,20201118,,HP,ZM,ZM,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Condition aggravated;Drug interaction;Drug resistance;Seizure;Virologic failure,185145341,OT,,,,,,,,,185145341,1,HIV infection
18518743,185187432,2,F,,20201127,20201119,20201130,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-096281,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20201130,,MD,PT,PT,EFAVIRENZ.,Drug resistance;Hepatic cirrhosis;Liver disorder,185187432,OT,,,185187432,1,,2014,,,185187432,1,Product used for unknown indication
18523637,185236371,1,I,,20201113,20201119,20201119,EXP,,CN-GILEAD-2020-0504783,GILEAD,,49,YR,A,F,Y,50,KG,20201119,,MD,CN,CN,EFAVIRENZ.,Hepatic function abnormal,185236371,HO,,,185236371,1,20200623,20200628,,,185236371,1,HIV infection
18523867,185238671,1,I,2004,20201112,20201119,20201119,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-096285,BRISTOL MYERS SQUIBB,,21,YR,,M,Y,,,20201119,,MD,PT,PT,EFAVIRENZ.,Alcoholism;Myocardial infarction;Pancreatitis acute;Treatment noncompliance,185238671,OT,,,185238671,1,2002,2004,,,185238671,1,Product used for unknown indication
18531452,185314521,1,I,,20201111,20201122,20201122,EXP,,CA-JNJFOC-20201124162,JOHNSON AND JOHNSON,,44,YR,A,M,Y,,,20201123,,HP,CA,CA,SUSTIVA,Abdominal pain;Anxiety;Constipation;Gastric infection;Muscle rigidity;Off label use;Pain;Product use in unapproved indication;Rebound effect;Retching;Salivary hypersecretion;Sedation,185314521,HO,,,,,,,,,185314521,1,Major depression
18531891,185318911,1,I,20200527,20201113,20201123,20201123,EXP,,CN-009507513-2011CHN009941,MERCK,,49,YR,,F,Y,50,KG,20201123,,HP,CN,CN,EFAVIRENZ.,Hepatic function abnormal,185318911,HO,,,185318911,1,20200602,20200623,,,185318911,1,HIV-associated neurocognitive disorder
18532546,185325461,1,I,2004,20201112,20201123,20201123,EXP,,PT-AUROBINDO-AUR-APL-2020-057303,AUROBINDO,,21,YR,,M,Y,,,20201123,,MD,PT,PT,EFAVIRENZ.,Alcoholism;Drug resistance;Myocardial infarction;Pancreatitis acute;Pathogen resistance;Treatment noncompliance,185325461,HO,,,,,,,,,185325461,1,Product used for unknown indication
18534358,185343582,2,F,,20201124,20201123,20201201,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020226365,VIIV,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV. DATA FROM A LONDON COHORT. J-VIRUS-ERAD. 2019;5(1):44-46",,,C,F,Y,,,20201201,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Depression;Drug resistance;Failure to thrive;Infertility;Lipodystrophy acquired;Ovarian failure;Portal hypertension;Treatment noncompliance,185343582,OT,,,185343582,1,1997,,,,185343582,1,HIV infection
18534361,185343612,2,F,,20201124,20201123,20201201,EXP,,GB-GLAXOSMITHKLINE-GB2020226365,GLAXOSMITHKLINE,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV. DATA FROM A LONDON COHORT. J-VIRUS-ERAD. 2019;5(1):44-46",,,C,F,Y,,,20201201,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Depression;Drug resistance;Failure to thrive;Infertility;Lipodystrophy acquired;Ovarian failure;Portal hypertension;Treatment noncompliance,185343612,OT,,,185343612,1,1997,,,,185343612,1,HIV infection
18535435,185354352,2,F,,20201130,20201123,20201205,EXP,,"PT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-062416",BOEHRINGER INGELHEIM,,55,YR,A,M,Y,,,20201205,,MD,PT,PT,EFAVIRENZ.,Drug resistance;Hepatic cirrhosis;Liver disorder,185354352,OT,,,185354352,2,,2014,,,185354352,1,Product used for unknown indication
18537314,185373142,2,F,,20201127,20201124,20201205,EXP,,PT-AUROBINDO-AUR-APL-2020-057306,AUROBINDO,,55,YR,,M,Y,,,20201205,,MD,PT,PT,Efavirenz Film Coated Tablets,Drug resistance;Hepatic cirrhosis;Liver disorder,185373142,OT,,,,,,,,,185373142,1,Product used for unknown indication
18537338,185373382,2,F,,20201120,20201124,20201130,EXP,,GB-AUROBINDO-AUR-APL-2020-057584,AUROBINDO,,,,C,F,Y,,,20201130,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Delayed puberty;Depression;Drug resistance;Failure to thrive;Infertility;Lipodystrophy acquired;Ovarian failure;Portal hypertension;Treatment noncompliance,185373382,OT,,,185373382,1,1997,,,,185373382,1,HIV infection
18544053,185440532,2,F,,20201111,20201124,20201125,EXP,,CA-JNJFOC-20201125727,JOHNSON AND JOHNSON,,44,YR,A,M,Y,,,20201125,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,185440532,HO,,,,,,,,,185440532,1,Depression
18547547,185475471,1,I,,20201117,20201126,20201126,EXP,,CA-ALVOGEN-2020-ALVOGEN-115287,ALVOGEN,,54,YR,,M,Y,,,20201126,,MD,CA,CA,SUSTIVA,Depression;Drug interaction,185475471,OT,,,,,,,,,185475471,1,Bipolar disorder
18549258,185492582,2,F,,20201130,20201126,20201204,EXP,IT-PFIZER INC-2020449099 (IT-PFIZER INC-2020449099),IT-IBIGEN-2020.09586,ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN),"TASCINI, C.. BREAKTHROUGH FUSARIUM SP PROBABLE PNEUMONIA DURING FLUCONAZOLE THERAPY IN AN AIDS PATIENT WITH DIABETES, CANDIDEMIA, PNEUMOCYSTIS CARINII PNEUMONIA AND CYTOMEGALOVIRUS DISSEMINATED INFECTION. JOURNAL OF CHEMOTHERAPY. 2006;18 (2):227-228. DOI:10.1179/JOC.2006.18.2.227",56,YR,,M,Y,,,20201130,,HP,IT,IT,EFAVIRENZ.,Drug ineffective;Pathogen resistance,185492582,DE,,,,,,,,,185492582,1,Adrenocortical steroid therapy
18549520,185495201,1,I,,20201123,20201126,20201126,EXP,,BR-AUROBINDO-AUR-APL-2020-058745,AUROBINDO,,,,I,F,Y,2.1,KG,20201126,,HP,BR,BR,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",Foetal exposure during pregnancy;Talipes,185495201,CA,,,,,,,,,185495201,1,HIV infection
18552079,185520791,1,I,,20201118,20201127,20201127,EXP,,FR-AUROBINDO-AUR-APL-2020-058453,AUROBINDO,,54,YR,,M,Y,,,20201127,,CN,FR,FR,EFAVIRENZ+EMTRICITABINE+TENOFOVIR FILM COATEDTABLETS,Acetabulum fracture;Amnesia;Arthritis;Osteoporosis;Pain;Rib fracture;Scoliosis,185520791,OT,,,185520791,1,2012,,,,185520791,1,HIV infection
18552722,185527221,1,I,,20201116,20201127,20201127,EXP,,CA-JNJFOC-20201134794,JOHNSON AND JOHNSON,,52,YR,A,M,Y,,,20201127,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,185527221,OT,,,,,,,,,185527221,1,HIV infection
18553185,185531853,3,F,20200917,20201211,20201127,20201216,EXP,,ZA-AUROBINDO-AUR-APL-2020-058798,AUROBINDO,,29,YR,,F,Y,,,20201216,,HP,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Abortion induced;Maternal exposure during pregnancy,185531853,OT,,,185531853,1,20200901,,,,185531853,1,Product used for unknown indication
18553217,185532171,1,I,,20201117,20201127,20201127,EXP,,CA-ALVOGEN-2020-ALVOGEN-115293,ALVOGEN,,54,YR,,M,Y,,,20201127,,MD,CA,CA,EFAVIRENZ.,Depression;Drug interaction;Loss of personal independence in daily activities,185532171,OT,,,,,,,,,185532171,1,Bipolar disorder
18553253,185532531,1,I,,20201125,20201127,20201127,EXP,,IT-AUROBINDO-AUR-APL-2020-058892,AUROBINDO,"TASCINI, C... BREAKTHROUGH FUSARIUM SP PROBABLE PNEUMONIA DURING FLUCONAZOLE THERAPY IN AN AIDS PATIENT WITH DIABETES, CANDIDEMIA, PNEUMOCYSTIS CARINII PNEUMONIA AND CYTOMEGALOVIRUS DISSEMINATED INFECTION.. JOURNAL OF CHEMOTHERAPY. 2006;18 (2):227-228",56,YR,,M,Y,,,20201127,,HP,IT,IT,EFAVIRENZ.,Drug ineffective;Pathogen resistance,185532531,OT,,,,,,,,,185532531,1,Fungaemia
18557618,185576181,1,I,,20201118,20201130,20201130,EXP,,IN-CIPLA LTD.-2020IN08985,CIPLA,"RUKMANGATHEN R, BRAHMANAPALLI VD, THAMMISETTY DP, PEMMASANI D, GALI SD, ATMAKURU RB. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECTIVES IN CLINICAL RESEARCH. 2020;11 (4):158 TO 163",,,,,Y,,,20201130,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness,185576181,OT,,,,,,,,,185576181,1,HIV infection
18557619,185576191,1,I,,20201118,20201130,20201130,EXP,,IN-CIPLA LTD.-2020IN08987,CIPLA,"RUKMANGATHEN R, BRAHMANAPALLI VD, THAMMISETTY DP, PEMMASANI D, GALI SD, ATMAKURU RB.. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI.. PERSPECTIVES IN CLINICAL RESEARCH. 2020;11(4):158 TO 163",,,,,Y,,,20201130,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness,185576191,OT,,,,,,,,,185576191,1,HIV infection
18557976,185579761,1,I,,20201118,20201130,20201130,EXP,,IN-CIPLA LTD.-2020IN08986,CIPLA,"RUKMANGATHEN R, BRAHMANAPALLI VD, THAMMISETTY DP, PEMMASANI D, GALI SD, ATMAKURU RB. STUDY OF ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL, TIRUPATI. PERSPECTIVES IN CLINICAL RESEARCH. 2020;11(4):158 TO 163",,,,,Y,,,20201130,,HP,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Deafness,185579761,OT,,,,,,,,,185579761,1,HIV infection
18559950,185599501,1,I,,20201116,20201130,20201130,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-101487,BRISTOL MYERS SQUIBB,"NDERITU P, RIGA P, MANN S, GARNAVOU-XIROU C, ELEFTHERIADIS H. DIDANOSINE-ASSOCIATED RETINAL TOXICITY (DART) AMONGST HIV-POSITIVE PATIENTS: A CASE SERIES AND LITERATURE REVIEW. COMPREHENSIVE CLINICAL MEDICINE. 2020",73,YR,,F,Y,,,20201130,,HP,GB,GB,EFAVIRENZ.,Retinal toxicity,185599501,OT,,,185599501,1,2003,2007,,,185599501,1,HIV infection
18561719,185617191,1,I,,20201123,20201201,20201201,EXP,,FR-ABBVIE-20K-056-3666544-00,ABBVIE,,,,,M,Y,,,20201130,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,185617191,OT,,,,,,,,,185617191,1,Maternal exposure timing unspecified
18570542,185705421,1,I,,20201123,20201202,20201202,EXP,,PH-SLATE RUN PHARMACEUTICALS-20PH000336,SLATE PHARMACEUTICALS,"CORTEZ SANTOS NJ, VILLEGAS TOMACRUZ ID, LANTION-ANG FL, SAN JUAN REYES PV.. AIDS PRESENTING AS RADIAL BONE TUBERCULOSIS AND PYOGENIC METHICILLIN-SENSITIVE STAPHYLOCOCCUS AUREUS OSTEOMYELITIS. BMJ CASE REPORTS. 2020;13",,,,,Y,,,20201202,,HP,PH,PH,EFAVIRENZ.,Acinetobacter infection;Neutropenia;Pneumonia;Staphylococcal infection;Staphylococcal sepsis,185705421,OT,,,,,,,,,185705421,1,Pneumonia
18574535,185745351,1,I,,20201123,20201203,20201203,EXP,,BR-MYLANLABS-2020M1099294,MYLAN,,,,I,F,Y,2.1,KG,20201203,,HP,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Talipes,185745351,OT,,,,,,,,,185745351,1,Product used for unknown indication
18576765,185767651,1,I,,20201120,20201203,20201203,EXP,,IT-BAUSCH-BL-2020-034456,BAUSCH AND LOMB,"TASCINI C, FERRANTI S, LEONILDI A, MENICHETTI F. BREAKTHROUGH FUSARIUM SP PROBABLE PNEUMONIA DURING FLUCONAZOLE THERAPY IN AN AIDS PATIENT WITH DIABETES, CANDIDEMIA, PNEUMOCYSTIS CARINII PNEUMONIA AND CYTOMEGALOVIRUS DISSEMINATED INFECTION. JOURNAL OF CHEMOTHERAPY. 2006;18(2):227-228. DOI:10.1179/JOC.2006.18.2.227",56,YR,,M,Y,,,20201203,,MD,IT,IT,EFAVIRENZ.,Fusarium infection,185767651,DE,,,,,,,,,185767651,1,Candida infection
18577265,185772652,2,F,2019,20201209,20201203,20201216,EXP,,KE-JNJFOC-20201150925,JOHNSON AND JOHNSON,,5,DEC,A,,Y,,,20201216,,HP,KE,KE,EFAVIRENZ;LAMIVUDINE;TENOFOVIR,Chest pain;Dyspnoea;Oxygen saturation decreased;Pulmonary embolism;Tachycardia,185772652,OT,,,,,,,,,185772652,1,Deep vein thrombosis
18578282,185782821,1,I,,20201130,20201204,20201204,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-102047,BRISTOL MYERS SQUIBB,,,,I,,Y,,,20201204,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,185782821,OT,,,,,,,,,185782821,1,Product used for unknown indication
18581664,185816641,1,I,,,20201203,20201203,DIR,,,FDA-CTU,,,,,F,N,,,20201202,N,HP,US,US,EFAVIRENZ/EMTRICIT/TENOFO 600/200/300MG TEVA PHARMACEUTICALS,Headache;Product substitution issue,,,185816641,HP,185816641,1,20201107,,,,185816641,1,Headache
18586990,185869901,1,I,,20201130,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100353,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",48,YR,,F,Y,,,20201207,,MD,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity;Visual field defect,185869901,OT,,,,,,,,,185869901,1,HIV infection
18586991,185869911,1,I,,20201130,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100352,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",33,YR,,M,Y,,,20201207,,MD,IN,IN,EFAVIRENZ.,Colour vision tests abnormal;Night blindness;Retinal toxicity,185869911,OT,,,,,,,,,185869911,1,HIV infection
18587001,185870011,1,I,,20201130,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100355,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",46,YR,,M,Y,,,20201207,,MD,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,185870011,OT,,,,,,,,,185870011,1,HIV infection
18587006,185870061,1,I,,20201130,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100354,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",51,YR,,,Y,,,20201207,,MD,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,185870061,OT,,,,,,,,,185870061,1,HIV infection
18587128,185871281,1,I,,20201130,20201207,20201207,EXP,,IN-MYLANLABS-2020M1100351,MYLAN,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR-IMMUNOL-INFLAMM 2020;28(7):1076-1084.",39,YR,,M,Y,,,20201207,,MD,IN,IN,EFAVIRENZ.,Colour vision tests abnormal;Night blindness;Retinal toxicity;Visual field defect,185871281,OT,,,,,,,,,185871281,1,HIV infection
18587242,185872421,1,I,,20191118,20201207,20201207,PER,,"US-LANNETT COMPANY, INC.-US-2019LAN001183",LANNETT,,34,YR,,F,Y,,,20201205,,HP,US,US,EFAVIRENZ.,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,185872421,1,Product used for unknown indication
18587246,185872461,1,I,,20191118,20201207,20201207,PER,,"US-LANNETT COMPANY, INC.-US-2019LAN001184",LANNETT,,,,,M,Y,3.02,KG,20201205,,HP,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;No adverse event,,,,,,,,,,,185872461,1,Product used for unknown indication
18587253,185872531,1,I,,20191118,20201207,20201207,PER,,"US-LANNETT COMPANY, INC.-US-2019LAN001191",LANNETT,,31,YR,,F,Y,,,20201205,,HP,US,US,EFAVIRENZ.,Maternal exposure during pregnancy;No adverse event,,,,,,,,,,,185872531,1,Product used for unknown indication
18587254,185872541,1,I,,20191118,20201207,20201207,PER,,"US-LANNETT COMPANY, INC.-US-2019LAN001192",LANNETT,,,,,F,Y,3.11,KG,20201205,,HP,US,US,EFAVIRENZ.,Foetal exposure during pregnancy;No adverse event,,,,,,,,,,,185872541,1,Product used for unknown indication
18588008,185880081,1,I,,20201127,20201207,20201207,EXP,,US-GLAXOSMITHKLINE-US2020GSK241890,GLAXOSMITHKLINE,,63,YR,,M,Y,,,20201207,,HP,US,US,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,185880081,OT,,,,,,,,,185880081,1,HIV infection CDC category B
18588009,185880091,1,I,,20201127,20201207,20201207,EXP,,US-VIIV HEALTHCARE LIMITED-US2020GSK241890,VIIV,,63,YR,,M,Y,,,20201207,,HP,US,US,EFAVIRENZ.,Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,185880091,OT,,,,,,,,,185880091,1,HIV infection CDC category B
18588224,185882241,1,I,,20201130,20201207,20201207,EXP,,NVSC2020PT320716,NOVARTIS,,55,YR,,M,Y,,,20201207,,HP,PT,PT,EFAVIRENZ.,Drug resistance;Hepatic cirrhosis;Liver disorder,185882241,OT,,,185882241,3,,2014,,,185882241,1,Product used for unknown indication
18588984,185889841,1,I,,20151210,20201208,20201208,PER,,US-009507513-1512USA010646,MERCK,,25,YR,,F,Y,,,20201208,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,185889841,1,20001109,20000810,,,185889841,1,HIV infection
18590594,185905941,1,I,1992,20201201,20201208,20201208,EXP,,US-GILEAD-2020-0506915,GILEAD,,57,YR,A,F,Y,,,20201208,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,185905941,OT,,,185905941,1,1990,1992,,,185905941,1,HIV infection
18597240,185972402,2,F,,20201208,20201209,20201217,EXP,,PT-MYLANLABS-2020M1099812,MYLAN,,55,YR,,M,Y,,,20201217,,MD,PT,PT,EFAVIRENZ.,Drug resistance;Hepatic cirrhosis;Liver disorder,185972402,OT,,,185972402,1,,2014,,,185972402,1,Product used for unknown indication
18599367,185993671,1,I,20191001,20201202,20201210,20201210,EXP,,ZA-GILEAD-2020-0507025,GILEAD,,20,YR,A,F,Y,,,20201210,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy,185993671,OT,,,,,,,,,185993671,1,Product used for unknown indication
18601761,186017612,2,F,,20201209,20201210,20201221,EXP,,GB-MYLANLABS-2020M1100529,MYLAN,"TEH J, PASVOL T, AYRES S, FOSTER C, FIDLER S.. CASE SERIES OF INFERTILITY AMONGST YOUNG WOMEN WITH PERINATALLY ACQUIRED HIV. DATA FROM A LONDON COHORT. J VIRUS ERAD.. 2019;5(1):44-46",28,YR,,F,Y,,,20201221,,HP,GB,GB,EFAVIRENZ.,Amenorrhoea;Depression;Lipodystrophy acquired;Off label use;Ovarian disorder;Ovarian failure;Portal hypertension,186017612,OT,,,,,,,,,186017612,1,Antiretroviral therapy
18601829,186018291,1,I,,20201202,20201210,20201210,EXP,,FR-MYLANLABS-2020M1100726,MYLAN,,54,YR,,M,Y,,,20201210,,CN,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acetabulum fracture;Amnesia;Arthritis;Osteoporosis;Pain;Rib fracture;Scoliosis,186018291,OT,,,186018291,1,2009,,,,186018291,1,HIV infection
18604399,186043992,2,F,,20201210,20201211,20201217,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015243,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",48,YR,,F,Y,,,20201217,,MD,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186043992,OT,,,,,,,,,186043992,1,HIV infection
18604401,186044011,1,I,,20201203,20201211,20201211,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015244,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",51,YR,,M,Y,,,20201211,,HP,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186044011,OT,,,,,,,,,186044011,1,HIV infection
18604406,186044061,1,I,,20201203,20201211,20201211,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015241,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",39,YR,,M,Y,,,20201211,,HP,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186044061,OT,,,,,,,,,186044061,1,HIV infection
18604407,186044071,1,I,,20201203,20201211,20201211,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015245,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",46,YR,,M,Y,,,20201211,,HP,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186044071,OT,,,,,,,,,186044071,1,HIV infection
18604408,186044081,1,I,,20201203,20201211,20201211,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP015242,STRIDES,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",33,YR,,M,Y,,,20201211,,HP,IN,IN,EFAVIRENZ.,Night blindness;Retinal toxicity,186044081,OT,,,,,,,,,186044081,1,HIV infection
18605949,186059491,1,I,,20201202,20201211,20201211,EXP,,IT-MYLANLABS-2020M1100626,MYLAN,"TASCINI, C.. BREAKTHROUGH FUSARIUM SP PROBABLE PNEUMONIA DURING FLUCONAZOLE THERAPY IN AN AIDS PATIENT WITH DIABETES, CANDIDEMIA, PNEUMOCYSTIS CARINII PNEUMONIA AND CYTOMEGALOVIRUS DISSEMINATED INFECTION. J. CHEMOTHER.. 2006;18 (2):227-228",56,YR,,M,Y,,,20201211,,HP,IT,IT,EFAVIRENZ.,Drug ineffective;Pathogen resistance,186059491,DE,,,,,,,,,186059491,1,Lung consolidation
18616933,186169331,1,I,,20201207,20201215,20201215,EXP,,IN-AUROBINDO-AUR-APL-2020-061297,AUROBINDO,,48,YR,,F,Y,,,20201215,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity;Visual field defect,186169331,OT,,,,,,,,,186169331,1,HIV infection
18617530,186175301,1,I,,20201207,20201215,20201215,EXP,,IN-AUROBINDO-AUR-APL-2020-061299,AUROBINDO,,46,YR,,M,Y,,,20201215,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity;Visual field defect,186175301,OT,,,,,,,,,186175301,1,HIV infection
18617553,186175531,1,I,,20201207,20201215,20201215,EXP,,IN-AUROBINDO-AUR-APL-2020-061298,AUROBINDO,,51,YR,,M,Y,,,20201215,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity;Visual field defect,186175531,OT,,,,,,,,,186175531,1,HIV infection
18619579,186195791,1,I,2016,20200723,20201215,20201215,PER,,TZ-LUPIN PHARMACEUTICALS INC.-2020-04165,LUPIN,,31,YR,,F,Y,,,20201215,,HP,TZ,TZ,TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Delivery;Exposure during pregnancy;Maternal exposure during breast feeding,,,,,186195791,2,2016,2016,,,186195791,1,Prophylaxis
18620585,186205851,1,I,,20201207,20201216,20201216,EXP,,IN-HETERO-HET2020IN01327,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",39,YR,,M,Y,,,20201216,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186205851,OT,,,,,,,,,186205851,1,HIV infection
18620755,186207551,1,I,,20201207,20201216,20201216,EXP,,IN-HETERO-HET2020IN01357,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",33,YR,,M,Y,,,20201216,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186207551,OT,,,,,,,,,186207551,1,HIV infection
18620816,186208161,1,I,,20201207,20201216,20201216,EXP,,IN-HETERO-HET2020IN01358,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",48,YR,,F,Y,,,20201216,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186208161,OT,,,,,,,,,186208161,1,HIV infection
18620885,186208851,1,I,,20201207,20201216,20201216,EXP,,IN-HETERO-HET2020IN01359,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",51,YR,,M,Y,,,20201216,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186208851,OT,,,,,,,,,186208851,1,HIV infection
18621009,186210091,1,I,,20201207,20201216,20201216,EXP,,IN-AUROBINDO-AUR-APL-2020-061295,AUROBINDO,,39,YR,,M,Y,,,20201216,,HP,IN,IN,EFAVIRENZ.,Colour vision tests abnormal;Night blindness;Retinal toxicity;Visual field defect,186210091,OT,,,,,,,,,186210091,1,HIV infection
18621048,186210481,1,I,,20201207,20201216,20201216,EXP,,IN-HETERO-HET2020IN01360,HETERO,"SUDHARSHAN S, KUMAR KD, BHENDE M, BISWAS J, SELVAMUTHU P.. EFAVIRENZ-ASSOCIATED RETINAL TOXICITY PRESENTING WITH NIGHT VISION DEFECTS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. OCULAR IMMUNOLOGY AND INFLAMMATION. 2020;28(7):1076-1084",46,YR,,M,Y,,,20201216,,MD,IN,IN,EFAVIRENZ.,Retinal toxicity,186210481,OT,,,,,,,,,186210481,1,HIV infection
18622037,186220371,1,I,,20201207,20201216,20201216,EXP,,IN-AUROBINDO-AUR-APL-2020-061296,AUROBINDO,,33,YR,,M,Y,,,20201216,,HP,IN,IN,EFAVIRENZ.,Retinal toxicity;Visual field defect,186220371,OT,,,,,,,,,186220371,1,HIV infection
18636166,186361661,1,I,,20201208,20201218,20201218,EXP,,FR-MYLANLABS-2020M1103008,MYLAN,,,,I,,Y,,,20201218,,CN,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,186361661,OT,,,,,,,,,186361661,1,Product used for unknown indication
18636808,186368081,1,I,,20201207,20201218,20201218,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-107851,BRISTOL MYERS SQUIBB,"CHEN J, CHEN R, SHEN Y, WEI H, WANG X, ZHANG R, ET AL. EFFICACY AND SAFETY OF LOWER DOSE TENOFOVIR DISOPROXIL FUMNARATE AND EFAVIRENZ VERSUS STANDARD DOSE IN HIV-INFECTED, ANTIRETROVIRAL-NAIVE ADULTS: A MULTICENTRE, RANDOMIZED, NONINFERIORITY TRIAL. EMERGING MICROBES + INFECTIONS. 2020;9 (1):843-50",,,A,M,Y,,,20201218,,HP,CN,CN,EFAVIRENZ.,Renal impairment,186368081,OT,,,,,,,,,186368081,1,HIV infection
18649151,186491511,1,I,,20201211,20201222,20201222,PER,,TH-LUPIN PHARMACEUTICALS INC.-2020-10740,LUPIN,,37,YR,,M,Y,,,20201222,,HP,GB,TH,EFAVIRENZ.,Toxic epidermal necrolysis,186491511,OT,,,,,,,,,186491511,1,Opportunistic infection prophylaxis
18652899,186528991,1,I,201912,20201215,20201223,20201223,EXP,,US-GILEAD-2020-0509350,GILEAD,,73,YR,E,F,Y,,,20201223,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,COVID-19,186528991,DS,,,,,,,,,186528991,1,Product used for unknown indication
18654345,186543451,1,I,20200731,20200910,20201223,20201223,EXP,,ZA-GILEAD-2020-0494586,GILEAD,,40,YR,A,F,Y,70.7,KG,20201223,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy;Transaminases increased,186543451,OT,,,186543451,1,20170309,20201216,,,186543451,1,HIV infection
18654547,186545471,1,I,2015,20201216,20201223,20201223,EXP,,US-GILEAD-2020-0509577,GILEAD,,,,E,M,Y,,,20201223,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Fall;Ligament sprain;Near death experience,186545471,OT,,,,,,,,,186545471,1,HIV infection
18659618,186596181,1,I,201901,20201218,20201223,20201223,EXP,,US-GILEAD-2020-0510286,GILEAD,,46,YR,A,M,Y,,,20201223,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density decreased;Rash;Renal injury;Weight increased,186596181,OT,,,186596181,1,20190201,201812,,,186596181,1,HIV infection
18663452,186634521,1,I,201810,20200506,20201224,20201224,EXP,,US-009507513-2012USA011140,MERCK,,,,,F,Y,,,20201224,,CN,US,US,SUSTIVA,Multiple fractures;Osteoporosis;Renal injury;Skeletal injury,186634521,OT,,,186634521,2,2004,,,,186634521,1,HIV infection
18664314,186643141,1,I,,20201103,20201225,20201225,PER,,US-LUPIN PHARMACEUTICALS INC.-2020-08812,LUPIN,,25,YR,,F,Y,,,20201225,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy,,,,,,,,,,,186643141,1,HIV infection
18666181,186661811,1,I,,20201103,20201226,20201226,PER,,US-LUPIN PHARMACEUTICALS INC.-2020-08822,LUPIN,,35,YR,,F,Y,,,20201226,,HP,US,US,EFAVIRENZ.,Exposure during pregnancy;Normal newborn,,,,,,,,,,,186661811,1,HIV infection
18674615,186746151,1,I,,20201216,20201229,20201229,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2020029578,MACLEODS,"SPIEGEL LR, SCHRIER PB, SHAH HH. SEVERE RECURRENT RHABDOMYOLYSIS-INDUCED ACUTE KIDNEY INJURY IN A HIV-INFECTED PATIENT ON ANTIRETROVIRAL THERAPY. RENAL FAILURE. 2013;35(8):1186-90",,,,,Y,,,20201229,,HP,US,US,EFAVIRENZ.,Alanine aminotransferase increased;Aspartate aminotransferase increased;Back pain;Blood creatine phosphokinase increased;Drug interaction;Swelling;Tenderness,186746151,HO,,,,,,,,,186746151,1,Antiretroviral therapy
18682327,186823271,1,I,,20201215,20201229,20201229,PER,,US-009507513-2012USA008427,MERCK,,53,YR,,F,Y,,,20201229,,HP,US,US,EFAVIRENZ.,Off label use,,,,,,,,,,,186823271,1,Mucormycosis
18686617,186866171,1,I,,20201228,20201230,20201230,EXP,,AU-ABBVIE-20K-008-3710226-00,ABBVIE,,,,,F,Y,,,20201230,,CN,AU,AU,EFAVIRENZ.,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging brain abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,186866171,OT,,,,,,,,,186866171,1,Product used for unknown indication
18687555,186875551,1,I,,20200925,20201231,20201231,PER,,ID-LUPIN PHARMACEUTICALS INC.-2020-07095,LUPIN,,29,YR,,F,Y,,,20201231,,HP,ID,ID,EFAVIRENZ.,Exposure during pregnancy,186875551,OT,,,,,,,,,186875551,1,HIV infection
18690228,186902281,1,I,20181215,20201216,20201231,20201231,EXP,,CN-GLAXOSMITHKLINE-CN2020APC251054,GLAXOSMITHKLINE,,36,YR,,M,Y,,,20201231,,HP,CN,CN,EFAVIRENZ.,Abdominal distension;Abdominal pain;Breath sounds abnormal;Bronchial wall thickening;Bronchogenic cyst;Central nervous system lesion;Condition aggravated;Cough;Decreased appetite;Disseminated tuberculosis;Drug interaction;Haemoglobin decreased;Hilar lymphadenopathy;Immune reconstitution inflammatory syndrome associated tuberculosis;Inflammation;Lung opacity;Lymph node abscess;Lymph node pain;Lymph node tuberculosis;Lymph node ulcer;Lymphadenopathy;Malaise;Myelosuppression;Necrosis;Nodule;Pneumocystis jirovecii pneumonia;Pneumothorax;Productive cough;Psoas abscess;Pulmonary tuberculosis;Pyrexia;Retroperitoneal lymphadenopathy;Therapeutic product effect incomplete,186902281,OT,,,186902281,1,20181115,,,,186902281,1,HIV infection
18690230,186902301,1,I,20181215,20201216,20201231,20201231,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2020APC251054,VIIV,,36,YR,,M,Y,,,20201231,,HP,CN,CN,EFAVIRENZ.,Abdominal distension;Abdominal pain;Breath sounds abnormal;Bronchial wall thickening;Bronchogenic cyst;Central nervous system lesion;Condition aggravated;Cough;Decreased appetite;Disseminated tuberculosis;Drug interaction;Haemoglobin decreased;Hilar lymphadenopathy;Immune reconstitution inflammatory syndrome associated tuberculosis;Inflammation;Lung opacity;Lymph node abscess;Lymph node pain;Lymph node tuberculosis;Lymph node ulcer;Lymphadenopathy;Malaise;Myelosuppression;Necrosis;Nodule;Pneumocystis jirovecii pneumonia;Pneumothorax;Productive cough;Psoas abscess;Pulmonary tuberculosis;Pyrexia;Retroperitoneal lymphadenopathy;Therapeutic product effect incomplete,186902301,HO,,,186902301,1,20181115,,,,186902301,1,HIV infection
7302622,730262233,33,F,,20200722,20100302,20201104,EXP,,CA-MERCK-0907CAN00093,MERCK,,52,YR,,M,Y,,,20201104,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,730262233,OT,,,730262233,7,200802,,,,730262233,1,HIV infection
